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Abstract 
 
THE ROLE OF THE NUCLEOSOME REMODELING FACTOR NURF IN INHIBITING T 
AND NATURAL KILLER CELL MEDIATED ANTITUMOR IMMUNITY BY 
SUPPRESSING TUMOR ANTIGENICITY AND NATURAL CYTOTOXICITY 
RECEPTOR CO-LIGANDS 
Kimberly Mayes, Ph.D.  
 
A dissertation submitted in partial fulfillment of the requirements for the degree Doctor of 
Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2017 
Advisor: Dr. Joseph Landry, Assistant Professor in Human and Molecular Genetics 
 
 Tumor immunoediting is a dynamic process in which the immune response 
attacks tumor cells by detecting danger signals and tumor antigens. In order to survive, 
tumor cells develop mechanisms to avoid detection or destruction by the immune 
system. To counteract this, several strategies are being developed to enhance the 
antitumor immune response, including the depletion of immunosuppressive cells, 
enhancing the activation of antitumor immune cells and increasing tumor cell 
immunogenicity. These therapies have seen limited success individually, however, and 
it is likely that combination therapy with novel targets will be necessary to see 
reproducible beneficial responses. Epigenetic modifications are attractive therapeutic 
targets because they are reversible and affect gene expression in cancer cells. Within 
xix 
 
this framework, this study aimed to elucidate the role of the chromatin remodeling 
complex nucleosome remodeling factor (NURF) in cancer immunoediting by silencing of 
bromodomain PHD-finger containing transcription factor (BPTF), the largest and 
essential subunit of NURF. Using two syngeneic mouse models of cancer, BPTF was 
found to suppress T cell antitumor activity in the tumor microenvironment. In vitro, 
enhanced cytolytic activity was observed for individual CD8 T cell clones only from mice 
bearing BPTF-silenced tumors, implicating the involvement of novel antigens. 
Mechanistic investigations revealed that NURF directly suppresses the expression of 
genes encoding immunoproteasome subunits Psmb8 and Psmb9 and the antigen 
transporter genes Tap1 and Tap2. PSMB8 inhibition reversed the effects of BPTF 
ablation, consistent with a critical role for the immunoproteasome in improving tumor 
immunogenicity. Thus, NURF normally suppresses tumor cell antigenicity and its 
depletion improves CD8 T cell antitumor immunity. In a concurrent study using different 
tumor lines, BPTF was also found to suppress natural killer (NK) cell antitumor immunity 
in vivo. Enhanced NK cell cytolytic activity toward BPTF-depleted targets in vitro was 
dependent on the natural cytotoxicity receptors (NCR). Molecular studies revealed that 
BPTF directly activates heparanase (Hpse) expression, resulting in reduced cell surface 
abundance of the NCR co-ligands: heparan sulfate proteoglycans. Thus, NURF 
represses NCR co-ligand abundance and its depletion enhances NK cell cytotoxicity. 
Therefore, NURF emerges as a candidate therapeutic target to enhance CD8 T or NK 
cell antitumor immunity. 
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Chapter 1 
Introduction 
Section 1.1: Cancer  
Cancer occurs when normal cells acquire several tumor-promoting 
characteristics. These characteristics are broadly organized into ten categories that 
have been widely accepted as hallmarks of cancer. The hallmarks are: resistance to 
apoptosis, inactivation of growth suppressors, induction of growth signals, unlimited 
replicative potential, angiogenesis, acquiring invasive and metastatic properties, 
deregulating energy metabolism, genomic instability, promoting tumor inflammation, and 
evading immune cell destruction (1). At a fundamental level, acquiring the hallmarks of 
cancer is a consequence of deregulating any one of a number of basic cellular 
properties including motility, differentiation, proliferation, and viability. In one theory, this 
occurs spontaneously as a result of somatic mutation (2). In some cases, these somatic 
mutations directly cause abnormal gene expression patterns favoring tumor cell growth. 
A classic example is the t(8;14)(q24; q32) translocation that juxtaposes the 
immunoglobulin heavy chain locus with the MYC protooncogene, elevating MYC 
expression (3,4). In other cases, mutations deregulate circuits resulting in the abnormal 
regulation of a large number of genes to favor tumor cell growth. Activating mutations in 
Ras (RasG12V), which result in tumor-promoting gene regulation, are a classic example 
(5,6). Once established, abnormal gene expression profiles maintain the tumor cell 
phenotype through a process of oncogene addiction (7). A breakdown of the DNA 
damage repair and maintenance mechanisms (nucleotide-excision repair instability, 
microsatellite instability and chromosomal instability) contributes to tumor cell genomic 
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instability and a higher rate of mutation. This instability results in the sporadic rise of 
clonal populations that have acquired new mutations, and ultimately a tumor comprised 
of a heterogeneous mixture of cells (1).  
In cancer therapy, individual hallmarks are targeted to disrupt tumor growth. For 
instance, radiation and chemotherapy target rapidly dividing tumor cells, and induce 
apoptosis through DNA damage. Angiogenesis and metastasis are targeted with drugs 
that inhibit growth factors, including vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF) (8,9). A number of drugs inhibit cancer 
metabolism by targeting catabolic pathways, anabolic pathways, and pathways 
regulating metabolism (10). Additionally, immunotherapy is a promising new approach 
aimed at enhancing tumor cell immunogenicity and antitumor immunity. Individual 
immunotherapies have seen great success in treating a subset of patients with specific 
cancer types. Combination treatment with multiple immunotherapy strategies is 
expected to see greater benefit (11). Therefore, this study aimed to discover a novel 
mechanism which could be targeted in cancer immunotherapy. 
1.1.1 Melanoma 
 Melanoma is one of the most immunogenic tumor types, due in part to a high 
mutation load. A significant initiator of mutations in melanoma is exposure to ultraviolet 
(UV) light. UV radiation causes two types of DNA damage: 6-4 photoproducts and 
pyrimidine dimers. Both lesions are formed by covalent linkages of the carbon atoms 
between two adjacent pyrimidines. When a cell is hit with DNA damage from UV 
radiation, it initiates G1 cell cycle growth arrest to repair the dimers by nucleotide 
excision repair (NER). Depending on if the DNA damage is repaired or not, the cell 
3 
 
either re-enters the cell cycle or undergoes apoptosis, respectively. These processes 
are all regulated by p53, a tumor suppressor which is mutated in approximately 50% of 
cancers. Thus, cells with mutated p53 are more susceptible to continued cell growth 
with unrepaired DNA (12). This unrepaired DNA damage is carcinogenic and is the 
primary source of mutations in melanoma. In fact, compared to other cancer types, 
melanoma tumors have a higher mutation load due to UV radiation. This high mutation 
load leads to the production and presentation of more immunogenic neoantigens, and 
thus a higher degree of immunogenicity (13). It is due to this high level of 
immunogenicity that makes melanoma tumors so responsive to immunotherapy. 
Markedly, melanoma is the most responsive solid tumor type, with significant success 
seen across multiple immunotherapy methods (11). 
Briefly, a few well-characterized oncogene driver mutations are key factors in 
melanoma transformation. First, around 50% of melanoma patients have a specific 
mutation in the BRAF oncogene- BRAF p.V600E (14). This mutation activates the 
serine/threonine kinase BRAF, which then stimulates the MAPK pathway. Two BRAF-
specific inhibitors (vemurafenib and dabrafenib) and a MEK1/2 inhibitor (trametinib) are 
used in the clinic to treat melanoma tumors with this mutation and prevent 
hyperactivated MAPK signaling (15). Around 20% of melanoma tumors have activating 
mutations in the NRAS oncogene, with the p.Q61R or p.Q61K mutations representing 
about 90% of NRAS activating mutations in patients (16). Activated NRAS promotes 
both the MAPK and PI3K signaling pathways. PI3K signaling activates another 
melanoma oncogene, RAS, whose expression can be necessary for melanoma tumor 
growth (17). However, no RAS specific inhibitors have been developed. For the 
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remaining ~30% of melanomas a driver mutation has not been established, though a 
number of candidates have been suggested based on exome sequencing (15).  
1.1.2 Breast Cancer 
 Unlike melanoma, breast cancer is a poorly immunogenic tumor type. There are 
three subtypes of breast cancer defined by hormone receptor expression. These 
subtypes are: estrogen receptor (ER) positive, human epidermal growth factor 2 
receptor (HER2) positive, and triple negative breast cancer (TNBC). ER-positive breast 
cancer tumors express ER and progesterone receptors (PR), which directly contribute 
to tumorigenesis through ER activation-dependent proliferation. While approximately 
65% of breast cancers are ER-positive, the mechanisms by which ER induces cell 
proliferation are not completely understood. It is known that an ER activated by its 
ligand homodimerizes and is translocated into the nucleus where it binds estrogen 
response elements in genes to regulate their activity. Independent of DNA binding, 
cytosolic ER can activate the ERK1/2 proliferation pathway (18). HER2-positive breast 
cancer is the second subset which comprises around 25% of breast cancers. These 
tumors have either HER2 gene amplification or overexpression. HER2 heterodimerizes 
with another HER family member upon ligand binding and overexpression contributes to 
tumorigenesis through multiple mechanisms. First, HER2 overexpression increases 
HER2 dimerization with HER3 and epidermal growth factor receptor (EGFR). HER2-
HER3 complexes activate the PI3K/Akt signaling pathway, which promotes cell 
proliferation and invasion. Second, HER2-EGFR complexes activate the Ras, PI3K and 
PLC-γ pathways, which induce cell cycle deregulation and invasive properties. Third, 
HER2 overexpression prolongs the activation of the downstream signaling pathways 
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MAPK and c-jun. It has also been proposed that an alternatively spliced HER2 transcript 
that is present in a majority of HER-positive tumors has enhanced tumor promoting 
abilities (19). There are not many cases in which breast tumors are both ER- and 
HER2-positive because estrogen represses HER2 expression (20). This occurs through 
estrogen-mediated downregulation of the transcription factor AP-2 and sequestration of 
the SRC-1 transcription factor (20). TNBC makes up about 20% of breast cancer tumors 
and is a highly heterogeneous subtype. TNBCs are more aggressive than hormone 
receptor-positive tumors and have a lower five year survival rate and a higher rate of 
relapse, partly due to the absence of hormone receptors, which can be targeted 
therapeutically (18).  
Endocrine therapy targeting hormone receptor positive breast cancer is a 
mainstay of cancer therapy. ER targeting therapies include the ER antagonist 
tamoxifen, the aromatase inhibitor anastrozole, the mTOR inhibitor everolimus and the 
CDK4/6 inhibitor palbociclib. HER2 specific therapies include trastuzumab and lapatinib 
and pertuzumab. Trastuzumab is a monoclonal antibody which binds to HER2 on cells 
and induces cell cycle arrest. Lapatinib is a tyrosine kinase inhibitor which disrupts 
HER2-EGFR signaling and pertuzumab is a monoclonal antibody which binds HER2 
and prevents it from dimerizing with HER3. While these targeted treatments drastically 
improve the survival of patients with hormone receptor positive breast cancer, 
development of tumor resistance to hormone therapy remains an issue. There are no 
targeted treatments for TNBC, though unlike hormone receptor positive tumors, TNBCs 
are responsive to chemotherapy (18).  
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Because there is no targeted treatment for TNBC, and resistance to hormone 
therapy is an issue with hormone receptor positive breast cancer, new strategies to treat 
breast cancer need to be developed. Interestingly, even though breast cancer is poorly 
immunogenic, tumor infiltration of lymphocytes is correlated with disease-free survival, 
indicating that the antitumor immune response is relevant to breast tumor growth (21). 
However, breast tumors are historically only minimally responsive to immunotherapy, 
due in large part to the lack of immunogenicity. Since tumor infiltrating lymphocytes are 
associated with positive outcome, methods which enhance the immunogenicity of 
breast tumor cells are a viable therapeutic strategy to improve tumor regression. 
Therefore, new methods enhancing tumor immunogenicity in combination with 
traditional immunotherapy could be the key to enhance the modest results seen with 
individual immunotherapies.  
Section 1.2: The Immune System 
 The immune system is composed of two arms: innate and adaptive immunity. 
Innate immunity provides the first wave of defense against infection. Innate immune 
cells include macrophages/monocytes, dendritic cells (DCs) and natural killer (NK) cells. 
These cells respond quickly to infection, but most pathogens cannot be cleared by 
innate immunity alone. Therefore, innate immunity serves two important auxiliary roles: 
to create an inflammatory environment and to prime immune cells of the adaptive 
response through immune cell infiltration and cytokine release. Adaptive immunity kicks 
in 4-7 days after the initial detection of an infection and it mounts a more effective attack 
against the pathogen. Cells of the adaptive immune response include CD4 T cells, CD8 
T cells and B cells. Importantly, adaptive immune cells retain memory of a pathogen, so 
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that if a second infection occurs by the same pathogen, the adaptive response can clear 
the re-infecting pathogen rapidly, without the time-consuming need for priming by innate 
cells (22). 
1.2.1 Antigen Presenting Cells 
 Antigen presenting cells (APC) present antigens resulting from an infection via 
either major histocompatibility (MHC) class I or II molecules to T cells. Through these 
functions, APCs prime T cells for T cell activation, expansion, and differentiation. 
Professional APCs include DCs, macrophages and B cells, DCs being the most 
physiologically important for T cell activation. DCs uptake antigens from different types 
of infections through phagocytosis, macropinocytosis, or from infection of the DC itself. 
Antigens engulfed by phagocytosis or macropinocytosis enter the endocytosis pathway 
and are presented on MHC II molecules to CD4 T cells, whereas antigens in the 
cytoplasm resulting from APC infection are presented by MHC I molecules to CD8 T 
cells. Antigens that are engulfed by DCs can also be cross-presented by MHC I 
molecules to CD8 T cells. Macrophages and B cells, on the other hand, use antigen 
presentation as a secondary line of defense. The primary function of macrophages is to 
engulf microbes and antigens for destruction, though they can present peptides from 
engulfed microorganisms on MHC II molecules. Antigen-specific B cells can bind 
antigens via their immunoglobulins, internalize them by receptor-mediated endocytosis 
and present the processed peptides on MHC II molecules. (22-24).  
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1.2.2 CD4 T Cells 
CD4 T cells, or helper T cells, do not directly kill target cells, but instead promote 
or inhibit the activities of other effector cells through cytokine secretion. CD4 T cell 
receptors (TCR) bind to antigens in complex with MHC class II molecules, which are 
restricted in expression to APCs. MHC II molecules specifically present peptides from 
the vesicular pathway, thus these antigens are of extracellular origin which have been 
endocytosed by the APC (22). 
Mature naive CD4 T cells are activated in the peripheral lymphoid tissue by 
interaction with an APC presenting the appropriate antigen. Following activation, and 
depending on the cytokine environment present, CD4 T cells differentiate into Th1, Th2, 
Th17, or regulatory T cells (Tregs) (22,25,26). Th1 cell differentiation is induced in the 
presence of DC and macrophage secreted interferon gamma (IFNγ) and interleukin 12 
(IL-12). Th1 cells are the primary CD4 T cell subset implicated in helping CD8 T cell 
activities through the production of IFNγ and IL-2. Induction of a Th1 response is 
necessary for the control of both bacterial infections and tumors. Th2 cell differentiation 
occurs in the presence of IL-4 and this subset promotes B cell activities through IL-4 
and IL-13 secretion. Th2 cells are mainly involved in the control of parasitic infections. 
Th17 cells arise in the presence of IL-6 and transforming growth factor beta (TGF-β) 
and are characterized by their secretion of the IL-17 family of cytokines. Th17 cells 
promote inflammation by recruiting innate immune cells, most prominently neutrophils. 
Treg differentiation can occur in the thymus, but can also be induced in the periphery 
under conditions of self-antigen recognition or in response to TGF-β. Tregs suppress 
immunity and maintain tolerance by multiple mechanisms. First, they produce TGF-β 
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and IL-10, which inhibit T cell proliferation and IL-2 production. IL-10 also suppresses 
the activity of DCs, which are necessary for T cell activation and Th1 differentiation. 
Tregs also express high amounts of the T cell co-inhibitory receptor cytotoxic T-
lymphocyte associated antigen 4 (CTLA-4), which competitively binds to the available 
B7-1, reducing the co-stimulatory potential for the surrounding T cells (25).  
1.2.3 CD8 T Cells  
Cytotoxic CD8 T cells are effector cells of the adaptive immune response which 
recognize antigens presented on MHC class I molecules. They have direct cytotoxic 
activities toward antigen expressing cells, typically virus infected cells or tumor cells. 
1.2.3.1 CD8 T Cell Maturation 
T cell development occurs in the thymus from committed lymphoid progenitor 
cells, which have migrated from the bone marrow. Committed lymphoid progenitors 
differentiate into double negative (DN: CD8-,CD4-) thymocytes, which express neither 
CD4 nor CD8. At the end of this developmental stage, DN thymocytes express either a 
γδ or an αβ TCR. In a subsequent developmental phase, DN thymocytes begin 
expressing both CD8 and CD4 to become double positive (DP: CD8+,CD4+) 
thymocytes. At this stage, medullary thymic epithelial cells (mTECs) present many self 
antigens to the DP thymocytes in a process called negative selection (27). In this 
process, a transcription factor called the autoimmune regulator (Aire) induces the 
expression of thousands of genes in mTECs whose expression is highly specific to 
certain tissue(s) (28,29). These tissue specific self antigens are presented on both MHC 
I and II molecules by mTECs and DCs to the DP thymocytes (30). Approximately 90% 
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of DP thymocytes do not signal, or signal very weakly, through their TCRs in response 
to antigen-MHC interaction. These thymocytes undergo death by neglect. Another 5% 
of DP thymocytes signal strongly in response to an antigen. These T cells are reactive 
to self antigens and are thus eliminated by negative selection via apoptosis in order to 
create T cell tolerance to self. The remaining 2-5% of DP thymocytes induce a signal of 
moderate strength through their TCRs, which stimulates their survival by positive 
selection. Depending on which antigen-MHC I or antigen-MHC II complex the TCR 
interacts with, the DP thymocyte will ultimately differentiate into a mature single positive 
(SP) CD8+,CD4- or CD8-,CD4+ T cell, respectively. SP thymocytes then proliferate in 
the thymus for about four days before migrating to peripheral lymphoid organs (31). 
Unlike innate immune cells which express an array of receptors that can 
recognize multiple ligands, each CD8 T cell expresses a TCR that is specific to an 
individual antigen (or, more likely, a set of similar antigens), thus providing a unique 
level of specificity. This is achieved through TCR V(D)J recombination during the DN 
and DP stages. Each TCR chain consists of a transmembrane constant (C) region 
which has signaling functions and an extracellular variable (V) region, which recognizes 
and binds to antigen. The variable region consists of two to three segments: the variable 
(V) and joining (J) segments of the TCR α and γ chains, and the V, diversity (D) and J 
gene segments of the β and δ chains. Each segment exists as multiple copies. The 
result of V(D)J rearrangement is one V, one D and one J segment forming the β chain 
variable region and one V and one J segment forming the ɑ chain variable region. Thus, 
the many possible combinations of individual V, J and/or D segment joining creates a 
high level of variable region diversity, called combinatorial diversity. Through this 
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process, the body’s T cell repertoire can recognize millions of different antigens, with 
each processed TCR specific to an array of related peptides (32). 
1.2.3.2 CD8 T Cell Priming 
 The last step of T cell maturation is priming in peripheral lymphoid tissues. DCs 
that have engulfed antigens migrate to the lymphoid organs near the site of infection, 
where they present the antigens via MHC class I or II to naive CD8 or CD4 T cells, 
respectively. T cell TCRs transiently bind DCs in lymphoid organs to sample the 
presented antigens. Naive T cells which encounter the appropriate antigen are activated 
by TCR signaling and undergo differentiation and proliferation. Naive T cells which do 
not encounter the correct antigen exit the lymphoid tissue and circulate via the blood 
through other lymphoid tissues until they encounter the proper antigen (22).  
T cell activation requires three signals: 1) TCR binding to the correct antigen-
MHC complex, 2) a co-stimulatory signal and 3) cytokines. These three signals provide 
vital regulation for the activities of T cells to respond to antigens only in the proper 
conditions of infection or cellular stress. For example, CD8 T cells which bind to a self 
antigen in the periphery undergo either apoptosis or anergy because a co-stimulatory 
signal is not sent in the absence of an inflammatory environment. In an immune 
response, the two main co-stimulatory ligands B7-1 and B7-2 are secreted by activated 
APCs. The receptor for B7-1 and B7-2 is CD28, expressed on T cells. This co-
stimulatory signal activates T cell cytokine production and proliferation as well as cell 
survival by inhibiting apoptosis and promoting cellular metabolism. On the flip side, co-
inhibitory signals negatively regulate CD8 T cell responses. Activated T cells express 
three co-inhibitory receptors: CTLA-4, programmed death 1 (PD-1) and B- and T-
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lymphocyte associated protein (BTLA). CTLA-4 binds the B7-1 and B7-2 ligands, PD-1 
binds to the PD-L1 and PD-L2 ligands, and the BTLA ligand is herpes virus entry 
mediator (HVEM) (33,34). In addition to antigen-MHC and co-stimulation, cytokines are 
also necessary for CD8 T cell function, IL-2 being the most important. IL-2 is secreted 
by activated DCs and CD4 T cells and is necessary for both CD8 T cell proliferation and 
differentiation following interaction with its antigen. While naive CD8 T cells can be 
activated by DCs alone, this process is often facilitated by CD4 T cells. CD4 T cells both 
maximize the DC co-stimulatory signal through CD40L/CD40 interaction and aid in CD8 
T cell proliferation and differentiation through IL-2 secretion (22,35). 
1.2.3.3 CD8 T Cell Activation  
Once the CD8 TCR has made contact with the appropriate antigen-MHC 
complex on an APC, a signal transduction cascade is activated which prompts the T cell 
to release the cytotoxic molecules perforin and granzymes or the Fas ligand (FasL). The 
TCR by itself does not have any signaling capacity; instead, the TCR associates with 
the co-receptor CD3, which contains ten intracellular immunoreceptor tyrosine-based 
activator motifs (ITAMs). Each ITAM contains two tyrosine residues that are 
phosphorylated upon TCR binding to antigen. ITAM phosphorylation is facilitated by 
CD8, whose extracellular domain interacts with the MHC complex. MHC binding 
stimulates activation of the tyrosine protein kinase Lck, which is associated with the 
intracellular domain of CD8, to phosphorylate the CD3 ITAM tyrosine residues. Tyrosine 
phosphorylation then allows the SH2 domain containing protein Zap-70 to bind. Zap-70 
is consequentially activated by phosphorylation by Lck and then activated Zap-70 
phosphorylates the adaptor proteins SLP-76 and LAT. The adaptor protein Gads 
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facilitates the interaction of activated SLP-76 and LAT, and this complex recruits the 
signaling protein PLC-γ. PLC-γ recruitment and activation is regulated both by the T cell 
co-stimulatory signal CD28, which is necessary for T cell activation, and by binding to 
the SLP-76:Gad:LAT complex. Recruited PLC-γ is then activated by tyrosine 
phosphorylation by Ltk. PLC-γ activation results in the activation of three separate 
pathways: the release of Ca2+ from the endoplasmic reticulum, the activation of the 
small GTPase Ras, and the activation of PKC-θ. First, activated PLC-γ stimulates the 
breakdown of PIP2 into DAG and IP3. IP3 then binds to its receptors on the endoplasmic 
reticulum membrane. These receptors are Ca2+ channels and IP3 binding results in their 
opening and Ca2+ release into the cytoplasm. Cytoplasmic Ca2+ binds to and activates 
the cytoplasmic protein calmodulin, which then activates calcineurin, which activates the 
NFAT family of transcription factors. NFAT transcription factors induce the expression of 
several genes important for T cell activation. Second, membrane bound DAG activates 
RasGRP, which in turn activates Ras. Ras stimulates a MAPK signaling cascade by 
phosphorylating and activating Raf. Raf then phosphorylates and activates MEK1, 
which phosphorylates and activates Erk. Erk activation ultimately stimulates the 
transcription factor AP-1. Third, DAG also activates PKC-θ, which then phosphorylates 
and activates the adaptor protein CARMA1. CARMA1 activates TRAF-6, which 
activates TAK1, which then activates IKK. IKK stimulates IκB degradation, which 
releases the NFκB family of transcription factors. NFAT, AP-1 and NFκB together 
directly regulate Il-2 expression (22,36,37).  
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1.2.3.4 Effector CD8 T Cells 
CD8 T cells differentiate into effector cytotoxic T cells (CTLs) and rapidly 
proliferate in response to Il-2 following activation, resulting in thousands of effector T 
cells with the same TCR. This is called clonal expansion. Effector CTLs cells then leave 
the lymphoid tissue and migrate through the blood and into the tissue at the site of 
infection. Unlike naive CD8 T cells, CTLs can respond to antigen without the need for a 
secondary co-stimulatory signal. After a CTL has made contact with the appropriate 
antigen-MHC complex on a target cell, the CTL’s local cytoskeleton is rearranged, 
which results in the excretion of preformed cytotoxic granules or FasL. Activated CTLs 
also release IFNγ and tumor necrosis factor alpha (TNF-α), cytokines which promote 
the immune response by helping activate macrophages and by upregulating the 
expression of MHC I molecules. 
In the case of cytotoxic granule release, which is the main mechanism by which 
CTLs kill targets, perforin and granzymes are secreted from the cytotoxic granules into 
the immunological synapse between the CTL and target cell. Perforin creates a pore in 
the target cell membrane, allowing granzymes entry into the cell. Granzymes are serine 
proteases and granzymes A and B are the most abundant in the cytotoxic granules. 
Granzyme A degrades the target cell nuclear envelope and induces single stranded 
nicks in the cellular DNA. Granzyme B cleaves BID and pro-caspase 3 to activate them. 
Caspase-3 activation triggers a caspase signaling cascade which ultimately results in 
CAD activation. CAD nuclease activity fragments the cellular DNA, an integral step in 
the apoptotic pathway. BID activation disrupts the outer mitochondrial membrane, 
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allowing the release of mitochondrial apoptotic enzymes such as cytochrome c into the 
cytoplasm (22,38,39).  
 In Fas mediated apoptosis, Fasl binding to its receptor Fas on the target cell 
induces Fas trimerization. This allows the cytoplasmic death domains of Fas to bind to 
the death domains of Fas-associated via death domain (FADD), an adaptor protein. 
Pro-caspase 8 and 10 then bind to the death effector domains of FADD, resulting in 
their self-cleavage, activation and disassociation from FADD. Caspase 8 activation 
initiates the apoptosis pathway (40). 
1.2.3.5 Memory CD8 T cells  
 After clearance of an infection, 95% of the clonally expanded effector T cells are 
eliminated by apoptosis. The remaining CD8 T cells have differentiated into memory T 
cells that can survive long term in the host, ready to quickly attack if a second infection 
occurs. Memory T cell differentiation is not fully understood, but it is believed that 
antigen signal duration, antigen signal strength and the cytokine environment all play 
important roles in determining the fate of effector T cells. It has been established, 
however, that memory T cell survival and maintenance depends on the cytokines IL-7, 
TSLP, and IL-15. Two types of memory T cells have been identified: central memory T 
cells (TCM) (CD62L+, CCR7+) and effector memory T cells (TEM) (CD62L-, CCR7-). 
TCM cells are primarily located in peripheral lymphoid tissues while TEM cells are 
located in nonlymphoid tissues such as the lung, liver and intestine (22,41,42). 
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1.2.4 γ:δ T Cells 
γ:δ T cells make up around 10% of all T cells and much less is known about this 
subset than the ɑ:β CD4 and CD8 T cells. γ:δ T cell development is dependent on 
whether a DN thymocyte expresses the pre-TCR or the γ:δ TCR first. As the γ:δ TCR 
requires more rearrangement steps than the pre-TCR, the pre-TCR is almost always 
expressed first. They are mostly located in mucosal and epithelial sites and they lack 
CD4 and CD8 molecules. Functions for γ:δ T cells include producing CXCL13 to 
regulate B organization and presenting antigens to both CD4 and CD8 T cells (43). 
1.2.5 MHC I Antigen Processing  
All nucleated cells express MHC class I molecules, which present intracellularly 
derived antigens to CD8 T cells. These antigens are byproducts of normal proteins 
called “self” antigens, antigens resulting from cell infection or antigens resulting 
from/associated with transformation.  
Proteins are broken down into antigens primarily by the constitutive proteasome. 
The proteasome is composed of a 20S catalytic domain and two 19S regulatory 
particles. The 19S regulatory particle recognizes ubiquitinated proteins and unfolds 
them so they can be fed into the 20S cylindrical core. The 20S core contains four 
stacked rings. The outer rings are composed of 7 alpha subunits each, which form a 
physical gate to the two inner rings, which are composed of 7 beta subunits each. The 
beta subunits create peptides by cleaving the protein at specific sites. Alternatively, 
three of the proteasome beta subunits can be substituted with PSMB8, PSMB9 and 
PSMB10, whose expression is upregulated upon type I or II IFN stimulation. The 
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PSMB8, PSMB9 and PSMB10 beta subunits have different cleavage specificities and 
cut proteins into more antigenic peptides than those processed by the constitutive 
proteasome (44). The PSMB8 and PSMB9 genes are located in the MHC region, while 
PSMB10 is not. This alternate form of the proteasome is called the immunoproteasome 
(45,46). This specialized proteasome ultimately creates peptides with higher affinity to 
MHC I molecules, which are therefore more antigenic to CD8 T cells (47,48). Both the 
proteasome and immunoproteasome cleave ubiquitinated proteins into peptides that are 
2-25 amino acid residues in length (49). These peptides are then transported into the 
endoplasmic ER by the transporter associated with antigen-processing (TAP) complex. 
The TAP complex is a heterodimer composed of the TAP1 and TAP2 subunits, which 
contain a hydrophobic transmembrane domain and a nucleotide binding domain (47). 
The TAP complex transports peptides, preferably between 8-12 residues, into the 
endoplasmic reticulum in an ATP-dependent manner. Interestingly, changes in 
expression of the TAP genes result in changes in the antigen repertoire presented at 
the cell surface (50). In the endoplasmic reticulum, peptides can be further cleaved by 
enzymes, like ERAP1, to fit into MHC I molecules. Fully processed antigens 8-10 amino 
acids long are then loaded onto MHC I molecules by the calnexin, calreticulin, ERp57 
and tapasin chaperones. ERp57 and tapasin can also remove low affinity peptides from 
the MHC I molecule and exchange them for higher affinity peptides (51). Peptide loaded 
MHC I molecules are then transported in vesicles to the cell surface. 
MHC I molecule expression is induced by IFN type I and II and consists of an α 
chain and a β chain. The α chain is composed of three domains (α1-α3) and the β 
domain is encoded by a single gene, β2-microglobulin (β2m). The α3 transmembrane 
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domain is bound noncovalently to α2m near the cell surface and the outer α2 and α3 
chains form the peptide binding cleft. MHC I molecules are highly polymorphic at this 
peptide binding cleft. There are three classical MHC I α chain genes in humans (HLA-A, 
-B and -C) and in mice (H2-K, H2-D and H2-L), each binding to a different range of 
peptides. There are approximately 800 alleles in the human population for each gene. In 
addition, multiple nonclassical MHC I molecules bind specialized peptides. This 
variability enables the MHC I molecule repertoire to bind to a wide selection of antigenic 
peptides (47).  
1.2.6 Myeloid Derived Suppressor Cells 
One immune cell type with remarkable ability to suppress the antitumor immune 
response in cancer is myeloid derived suppressor cells (MDSC). MDSCs originate from 
immature myeloid cells and myeloid progenitor cells. During the normal state, these 
myeloid cells differentiate into granulocytes, macrophages or DCs, thus MDSCs do not 
represent a significant population of mature immune cells, nor do they have significant 
roles in immune biology. However, tumor cells can secrete cyclooxygenase 2, 
prostaglandins, stem-cell factor, IL-6, VEGF, granulocyte macrophage colony-
stimulating factor (GM-CSF) and/or macrophage CSF (M-CSF), which induce MDSC 
differentiation and expansion. In this way MDSCs are significantly amplified and can 
represent up to 40% of white blood cells in the spleen of tumor bearing mice (22,52). 
Two distinct subsets of MDSCs have been identified: granulocytic and monocytic 
MDSCs. Granulocytic MDSCs represent the majority of expanded MDSCs and have 
different molecular functions than their monocytic counterparts. Monocytic MDSCs have 
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the unique ability to further differentiate into DCs and tumor associated macrophages 
(53).  
MDSCs are activated by T cell and tumor stromal cell secreted INFγ, IL-4, IL-13 
and TGF-β. Activated MDSCs efficiently inhibit the T cell response through a few 
mechanisms. First, they express high amounts of arginase 1 (Arg1) and inducible nitric 
oxide synthase (iNOS), which metabolize and thereby deplete the non essential amino 
acid arginase. Because arginase is essential for T cell proliferation, arginase depletion 
by MDSCs handicaps T cell expansion. MDSCs also produce nitric oxide (NO) and 
reactive oxygen species (ROS), which induce T cell apoptosis and produce 
peroxynitrite. Peroxynitrite in the tumor microenvironment stimulates the nitration of the 
cysteine, methionine, tryptophan and tyrosine amino acids of the TCR. These post-
translational modifications result in the inability of the TCR to respond to antigen (53). It 
has also been shown that MDSCs can induce the differentiation of tumor infiltrated T 
cells into Tregs (54). In addition, T cells rely on APCs to secrete cysteine, which they 
then uptake from the microenvironment for metabolism. MDSCs import and sequester 
the available cysteine, preventing adequate uptake by T cells (55). MDSCs also 
produce the immunosuppressive cytokines IL-10, TGF-β and COX2 (52). 
Besides T cells, MDSCs also inhibit NK cells and DCs. MDSCs can suppress NK 
cell cytotoxicity and induce anergy through TGF-β and STAT5 and Arg (55-57). They 
also suppress NK cell NKGD expression and IFNγ production (55). Tumor infiltrated DC 
function is also repressed through several mechanisms. MDSCs prevent DC 
maturation, which is required for antigen presentation to T cells, they suppress DC 
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antigen uptake and they inhibit DC migration. Further, MDSCs can also promote the 
expression of anti-inflammatory cytokines by DCs (58). 
1.2.7 Natural Killer Cells 
NK cells are cells of the innate immune response that target bacteria infected 
cells, virus infected cells, or transformed cells without prior sensitization. NK cells 
develop from common haematopoietic precursor cells predominantly in the bone 
marrow, but also at peripheral sites including the liver, lymph nodes, thymus and uterus 
(59). NK cell activity is positively regulated by activating receptors and by dendritic cell 
or macrophage secreted cytokines, including type I IFN (cytotoxicity), IL-15 (survival 
and proliferation), IL-12 (IFN-𝜸 production), IL-2 (cytolytic activity) and IL-18 
(cytotoxicity) (60). NK inhibitory receptors, on the other hand, provide negative 
regulation. 
Mature NK cells express a variety of activating and inhibitory receptors and the 
net effect of ligand interaction from a target cell determines whether an inhibitory or 
activating response is induced. In order to prevent autoimmunity to healthy cells, most 
inhibitory receptors recognize “self” MHC I molecules, which all nucleated cells express. 
Downregulation of MHC molecules following viral infection or transformation can induce 
a “missing-self” NK response. Inhibitory receptors signal through immunoreceptor 
tyrosine-based inhibitor motifs (ITIMs) in their cytoplasmic tails. To detect pathogen 
infected or tumor cells, activating receptors recognize pathogen-associated molecular 
patterns (PAMPs), damage-associated molecular patterns (DAMPs), or viral ligands 
themselves. These receptors’ ligands are much less well-defined than the inhibitory 
receptors’ and for multiple activating receptors, their ligands have yet to be discovered 
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(22). The two main activating receptor families involved in tumor immunoediting are 
NKG2D and the natural cytotoxicity receptors (NCR). NKG2D, expressed by both 
mouse and human NK cells, is the best characterized NK activating receptor. NKG2D 
binds the cellular stress induced nonclassical MHC molecules Rae1 and H-60 in mice, 
which can result in tumor elimination in vivo (61,62). In fact, most tumors express 
NKG2D ligands (63). NKG2D also binds the human CMV ligand ULBP. Another class of 
receptors involved in antitumor immunity which are much less characterized are the 
NCRs. The NCRs bind unknown tumor ligands in combination with the co-ligand 
heparan sulfate (HS). Generally, activating receptors signal through ITAMs associated 
with their cytoplasmic domains, which results in NK degranulation and transcription of 
cytokines. CD16 (FcγRIIa) is unique activating NK receptor which binds to the Fc 
portion of immunoglobulins bound to target cells and triggers antibody-dependent 
cellular cytotoxicity (ADCC) by signaling through its ITAM (64). Like CD8 T cells, while 
activated NK cells can kill targets through either perforin/granzyme release or through 
the Fas-FADD pathway, the perforin-dependent pathway is the most physiologically 
relevant pathway in vivo (65). Unlike CD8 T cells, NK cells don’t rapidly proliferate 
following activation. 
There are two main NK cell subsets in human: CD56dimCD16+ and 
CD56brightCD16-. CD56dim NK cells are highly cytotoxic and can secrete IFNγ (66). This 
subset constitutes the majority of NK cells in humans. Only a small proportion of human 
NK cells are CD56bright and these poorly cytotoxic NK cells are the source of most NK 
secreted cytokines, including IFNγ, TNF-α, TNF-β, IL-10, IL-13 and GM-CSF (67). 
Mouse NK cells also have cytotoxic and cytokine secreting functions, though identifying 
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two functionally distinct NK cell subsets is less clear because mouse NK cells do not 
express CD56 (68).  
 In addition to killing infected and malignant cells, activated NK cells also regulate 
the activities of DCs, CD4 T cells and CD8 T cells through cytokine secretion. For 
example, NK cells enhance T cell activity through secretion of IFNγ, which stimulates 
DC maturation and CD4 T cell differentiation into the Th1 phenotype, further promoting 
the immune response (69,70). On the other hand, during certain viral infections NK cells 
secrete IL-10, which suppresses the T cell response (71,72). NK cells can also directly 
kill Tregs and activated CD8 T cells expressing NKG2D or NCR1 ligands and activated 
CD4 T cells with downregulated Qa1 (73-75).  
1.2.7.1 Natural Cytotoxicity Receptors 
One key class of NK cell activating receptors that recognizes tumor ligands is the 
NCRs (76,77). There are 3 NCRs in humans (NKp30, NKp44, and NKp46) and 1 in 
mice (NCR1). These receptors have essential functions in NK cell-mediated antitumor 
immunity, including controlling tumor growth and metastasis in vivo, and cytolytic and 
cytotoxic activity in vitro (78-81). These receptors belong to the immunoglobulin 
superfamily. They have one (NKp30, NKp44) or two (NKp46) extracellular 
immunoglobulin-like domains which bind ligand and a transmembrane domain which 
contains a positive amino acid that binds signaling adaptor proteins containing ITAMs 
(or an ITIM for NKp44) (76). Both human and mouse NCRs recognize N- and O-sulfo 
modified HS, which is located on the plasma membrane as heparan sulfate 
proteoglycans (HSPG). NKp30 and NKp46 exhibit similar binding patterns to HS, but 
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with different affinities, while NKp44 exhibits a completely different binding pattern to HS 
chains (82).  
The NCRs recognize ligands from a variety of sources. NKp44 and NKp46 
recognize hemagglutinin (HA) and hemagglutinin neuraminidase (HN) from multiple, but 
not all, viruses. NCR recognition of HA or HN seems to be based on posttranslational 
modification of the receptor (76). NKp30 recognizes pp65 from cytomegalovirus, which 
inhibits NK activity (83). NKp44 can also bind to and is activated by envelope 
glycoproteins of West Nile virus (84) and vimentin, a ligand expressed by cells infected 
with Mycobacterium tuberculosis (85). NKp46 can be activated by a bacterial ligand of 
Fusobacterium nucleatum and a ligand expressed by pancreatic β Langerhans cells 
(86,87). B7-H6, expressed by tumor cells and inflammatory innate immune cells is a 
well-characterized ligand for NKp30 (76,88). For other potential NCR ligands like BAT3, 
PCNA and a Plasmodium falciparum ligand, there are conflicting reports on whether or 
not they elicit NK responses (76). Thus, NCRs have been implicated in killing virus and 
bacteria infected cells, as well as play a role in diabetes and antitumor immunity.  
Structurally, NKp30 and NKp46 are similar to each other. Both have an arginine 
amino acid in their transmembrane domains that associates with an FcRγ signaling 
domain containing intracellular ITAMs. NKp30 and NKp46 engagement results in 
tyrosine phosphorylation of the associated ITAMs by srk-family kinases. This allows 
binding of Syk and ZAP70 to the ITAM sequence, where they recruit and phosphorylate 
the adaptor molecule LAT and NTAL. These molecules then recruit and phosphorylate 
phospholipase C, Vav2, Vav3 and PI3K. The Vav molecules have guanine exchange 
factor activity and activate the GTPases Rho and Rac1. These GTPases activate the 
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MAPK signaling pathway, which is important for NK cell degranulation. Phospholipase C 
activation stimulates the release of Ca2+ into the cytosol, leading to the secretion of 
cytokines. PI3K activation induces the expression of genes involved in cytoskeletal 
rearrangement (77,89). 
1.2.8 Heparan Sulfate 
HSPGs are core proteins with HS glycosaminoglycan side chains covalently 
attached. Transmembrane HSPGs are called syndecans, GPI linked HSPGs are called 
glypicans and HSPGs which are shed are called perlecans. HS is a highly structurally 
diverse molecule which sequesters growth factors, coagulation factors, proteases, 
morphogens, cytokines, chemokines and cell adhesion molecules at the cell surface to 
regulate the extracellular matrix (ECM) structure, cell signaling and cell adhesion 
(90,91). HS synthesis occurs in the Golgi apparatus, is non-template driven and 
involves multiple enzymes including glycosyltransferases, sulphotransferases and 
epimerases. HS synthesis is tightly regulated and tissue and cell-type specific. All 
animal cells have cell surface HS, but HS structure is different between tissue types and 
between healthy vs tumor cells (92). 
 In cancer biology, cell surface and soluble HS have multiple functions in DAMP 
signaling. DAMPs are danger signal molecules released by necrotic cells to promote 
tissue repair and the inflammatory response. On endothelial cells, HS is necessary for 
oligomerization of RAGE, the receptor for the DAMP molecules HMGB1 and 
S100A8/A9. HSPG interactions are also necessary for HMGB1 and S100A8/A9 binding 
to the endothelial cell surface (93,94). In addition, soluble HS can act as a DAMP 
molecule itself by binding to the toll-like receptor 4 (TLR-4) on dendritic cells and 
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causing dendritic cell maturation (95). Soluble HS also acts as a DAMP by stimulating 
the release of inflammatory cytokines by macrophages in vitro (96). 
1.2.9 Heparanase 
The only known HS modifying enzyme in mammals is heparanase. Heparanase 
is an endo-B-glucuronidase with demonstrated specificity for multiple HS substrates, 
though the exact requirements for heparanase activity are not fully understood (97). 
Two heparanase genes have been identified that are highly homologous to each other, 
heparanase-1 and heparanase-2. Only heparanase-1, however, has HS-degrading 
activity. Heparanase-1 and heparanase-2 have distinctly different patterns of expression 
in tissues and it has been suggested that heparanase-2 acts as an inhibitor of 
heparanase-1 by binding to HS and heparanase-1 (98,99). Further, the human 
heparanase-1 gene generates two different mRNA forms by alternative splicing, though 
both forms have the same open reading frames and produce the same polypeptide 
amino acid sequence (100,101). 
Heparanase-1 (further referred to as heparanase) activity in the ECM is tightly 
controlled through regulations at three different stages in its life cycle: transcription, 
cellular uptake and secretion of active heparanase. First, heparanase expression is 
constitutively suppressed in most cell types by promoter methylation; treatment with the 
demethylating agent 5-azacytidine stimulates heparanase re-expression (102). 
Heparanase expression is also regulated by p53, Sp1, GABP, EGR1 and estrogen 
(103-107). Heparanase is translated as a 65 kilodalton (kDa) proenzyme and is then 
secreted from the cell, where it can interact with HSPGs on the cell surface. 
Heparanase binding to HS side chains attached to syndecan-1, syndecan-4, lipoprotein 
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receptor-related proteins or Man-6-P triggers endocytosis of the HSPG and 
heparanase. This endocytosis step is efficient as latent heparanase does not 
accumulate in growth medium (108-110). The endosome then transitions into a 
lysosome, allowing for activation of the enzyme cathepsin L. Activated cathepsin L 
cleaves 6 kDa from heparanase to create an 8 kDa and 50 kDa heterodimer. This is the 
active form of heparanase (111,112). Active heparanase is stored in the lysosome until 
prompted for secretion from the cell. This step is regulated by stimuli like TNF-α, IL-1β, 
fatty acids, ATP, ADP, and adenosine (113,114). Active heparanase secreted from the 
cell cleaves 4-7 kDa HS fragments from cell surface HSPGs (115). Active heparanase 
can also be translocated to the nucleus, where it possibly binds to nuclear HS and it has 
been suggested that heparanase in the nucleus can affect gene transcription by 
increasing histone H3 expression or through indirectly enhancing histone 
acetyltransferase (HAT) activity (116,117).  
Heparanase is frequently upregulated by cancer cells to regulate cell motility, 
metastasis, angiogenesis and inflammation (118). Heparanase promoter 
hypomethylation is a common event in cancer cells which upregulates heparanase 
expression. Additionally, wildtype p53 directly inhibits heparanase at the promoter. p53 
is mutated in around 50% of cancers, however, and mutated p53 does not have the 
ability to bind to the heparanase promoter (103). ETS1 and ETS2 have also been 
shown to promote heparanase expression in metastatic breast cancer cells through 
binding to two ETS binding sites in the promoter (119). Because heparanase expression 
is repressed by promoter methylation, treatment with 5-azacytidine, a DNA methylation 
inhibitor that is FDA approved for the treatment of AML and chronic myelomonocytic 
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leukemia, upregulates heparanase expression (120). Enhanced heparanase activity in 
cancer results in increased cleavage of HS and bound bioactive molecules from the 
membrane and degraded ECM structure. These soluble molecules contribute to tumor 
progression by promoting metastasis, angiogenesis and inflammation. One important 
property of metastatic cells is the ability to degrade cell surface HS to disrupt cell 
adhesion. Strikingly, ectopic heparanase expression is sufficient to make poorly 
metastatic T-lymphoma and melanoma cells highly metastatic (121). Heparanase-
mediated release of sequestered angiogenic factors like basic fibroblast growth factor 
(bFGF) and VEGF and promotes angiogenesis (122). High heparanase expression in 
vivo is accompanied by increased vascularization throughout breast tumors and 
increasing vessel density and maturation (123). Released growth factors also stimulate 
tumor growth by binding growth receptors on nearby tumor cells. In addition, 
heparanase regulates inflammation through the release of HS bound cytokines and 
chemokines and through activation of innate immune cells by interactions of soluble HS 
with TLRs (124). Heparanase was reported to drive inflammation induced esophageal, 
pancreatic, hepatocellular and colon carcinoma (125-128). Outside of tumor 
immunology, heparanase has consequences to autoimmune disorders, diabetes and 
restenosis. Heparanase-2, on the other hand, is not upregulated in cancer and studies 
show that expression negatively correlates to disease-free survival and aggressiveness 
(98,99,129). 
Heparanase expression in human tumors is a robust marker for poor prognosis 
and patients with low heparanase expression live longer than those with high 
expression (130-134). Because high heparanase expression is common to many cancer 
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types and promotes tumor cell biology, inhibition of heparanase has been explored as a 
therapeutic strategy. A multitude of heparanase inhibitors have been developed 
including heparin analogs (PI-88, Suramin, PG545, PS3, JG3, STMC, SST0001, M402), 
small molecule inhibitors (2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acids, 
furanyl-1,3-thiazol-2-yl-acetic acid derivatives, benzoimidazol-2-yl-benzamides, 4-(1H-
benzoimidazol-2-yl)-phenyl-ureas, Quinolines, DMBO) and compounds from natural 
products (Trachyspic acid, CRM646, RK-682, Echinoside A). These drugs all 
demonstrated a degree of anti-tumorigenic, anti-angiogenic or anti-metastatic properties 
in preclinical studies or clinical trials (135). However, the most promising heparanase 
inhibitor, PI-88, failed to improve disease free survival in a phase III clinical trial 
(NCT01402908). Importantly, none of the heparanase inhibitors tested are specific to 
heparanase. Thus, there is a need for a specific heparanase inhibitor. 
Section 1.3: Tumor Immunology 
1.3.1 Cancer Immunoediting 
Immunoediting describes the process by which the immune system shapes the 
immunogenicity of the tumor through immune selection and tumor adaptation. There are 
three phases in immunoediting: elimination, equilibrium and escape.  
In the elimination phase, the immune system is able to recognize and kill transformed 
cells before the tumor can develop resistance. If tumor elimination is successful, the 
transformed cells are eliminated very early in tumor development, before a clinically 
diagnosable tumor has formed. Evidence for the immune system quelling spontaneous 
tumor growth comes from high incidence rates of cancer in immunosuppressed 
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recipients of transplants compared to the general population. Biologically, the immune 
response recognizes alarm signals resulting from deregulated genes and pathways in 
the tumor. For example, tumor cell growth is characterized by stromal remodeling, 
which produces danger signals and chemokines. These signals recruit innate immune 
cells such as macrophages, NK cells and DCs to the tumor. Activated macrophages 
produce INFγ, which provides a positive feedback signal for the immune response and 
NK cells kill tumor cells expressing NK receptor ligands resulting from cellular stress. 
DCs endocytose peptides from dying tumor cells and present them to CD4 T cells or 
cross-present them to CD8 T cells. These peptides can include tumor associated 
antigens and/or tumor specific antigens. Tumor-specific T cells migrate to the tumor 
where they produce IL-2 and kill antigen positive cells (136). 
In the equilibrium stage, tumor variant(s) have developed resistance to total 
elimination, but suppression of further growth is constantly maintained by the immune 
system. This phase can last years in humans before the acquired mutation load allows 
the cells to enter into the escape phase. This phenomenon was evident through 
transmission of cancer following organ transplantation. In two specific cases, recipients 
who did not have any history of melanoma received an organ from donors who had 
been in remission for many years after successful treatment of melanoma. After 
transplantation, the donors remained cancer free while the recipients developed 
melanoma (137,138). The combination of a suppressed immune system and the lack of 
adaptive immunity to the transplanted cancer cells led to escape phase tumor growth in 
the recipients while an educated and active immune system in the donors continued to 
contain the tumor cells in an equilibrium.  
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In the escape phase, tumor variants have developed multiple mechanisms to 
suppress or avoid the antitumor response. These tumor cells are therefore able to grow 
virtually unchecked by the immune system. Common escape mechanisms include 
antigen and MHC loss, NK ligand shedding, recruitment of regulatory immune cells such 
as Tregs, MDSCs and M2 macrophages (tumor promoting macrophage subset), release 
of immunosuppressive cytokines such as TGF-β and IL-10, and developing insensitivity 
to IFNγ. Four of the most frequent escape mechanisms in human tumors are human 
leukocyte antigen (HLA) class I, TAP1, PSMB8 and PSMB9 loss (139-141). The escape 
phase of tumor growth is the most clinically relevant as tumors which present in the 
clinic are in this phase. Thus the goals of immunotherapy are to break the established 
immunosuppressive mechanisms and re-activate antitumor immunity (136). 
1.3.2 Tumor Antigens 
There are three types of tumor antigens which CD8 T cells recognize: tumor 
associated antigens (TAA), tumor specific antigens (TSA) and cancer testis antigens 
(CTA). TAAs are antigens derived from proteins that are tissue- or development- 
restricted in expression. While these genes can be expressed by normal tissue, they are 
overexpressed in tumor cells and may directly promote tumor cell biology. A few 
examples of melanoma TAAs include gp100 and TRP-1, which are both epitopes from 
tyrosinase, and MART-1, an antigen from Melan-A (142).  
TSAs are antigens derived from proteins that are specifically expressed by tumor 
cells as a result of mutation, gene fusion from a chromosomal translocation, aberrant 
posttranslational modification, or from an oncogenic viral protein. Tumor cells usually 
have a high mutation load, mainly due to carcinogens and genomic instability, and these 
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mutations can be missense mutations, frameshift mutations, insertions or deletions. 
Unlike TAAs, TSAs are specific to the individual mutations of a patient, which are highly 
variable from one individual to the next (143). The best understood aberrant 
posttranslational modification resulting in TSAs is protein hyperphosphorylation. Tumor 
cells commonly deregulate protein kinase activity, resulting in an array of 
hyperphosphorylated peptides which more stably bind MHC I molecules (144). Protein 
glycosylation is another posttranslational modification that is frequently deregulated in 
tumor cells and can create TSAs (145).  
CTAs are antigens derived from proteins restricted in expression to germline 
cells- the testis or placenta (143). In somatic cells, their expression is constitutively 
repressed by methylation and histone posttranslational modifications (146). In tumor 
cells and during development in germ cells, a wave of global hypomethylation induces 
the expression of these genes (147-149). These germline gene products, when broken 
down, create new antigens for T cell recognition. Because CTAs are broadly expressed 
across many cancer types and not expressed by most normal tissue, they are ideal for 
immunotherapy (146). The most frequently expressed CTAs include the melanoma 
antigen (MAGE) family, New York oesophageal squamous cell carcinoma 1 (NY-ESO-
1) family and synovial sarcoma/X breakpoint 2 (SSX-2) antigens (150-152).  
Section 1.4: Immunotherapy 
 Ever since the impact of the immune system on tumor growth was understood, 
there has been great interest in developing strategies to improve the antitumor immune 
response. Many immunotherapeutic methods targeting different aspects of the 
antitumor response have been developed. These include approaches to activate 
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immune cells (cytokine therapy, antigen vaccination), to dampen immunosuppressive 
mechanisms (checkpoint blockade, TGF-β inhibition) and to expand the infiltration and 
activities of effector cells (T or NK cell adoptive cell therapy). Unfortunately, there has 
been limited success with immunotherapy so far, with only a few treatments FDA 
approved to date (11). There is expectation, however, that with further research and 
with combination therapy using multiple immunotherapeutic strategies or standard 
chemotherapy will be necessary to bring about the full potential for individual 
immunotherapy methods. 
1.4.1 Cytokine Therapy 
One approach to enhance immune cell activities to tumors is cytokine therapy. 
Cytokines are integral for immune cell activation and maintenance and for influencing 
the type of response the immune system initiates. Two cytokine treatments have 
achieved FDA approval so far- IL-2 and IFNα. IL-2 is the main cytokine necessary for T 
cell activation and high dose treatment has been approved for melanoma and renal cell 
carcinoma. However, a broad applicability of high dose IL-2 treatment is limited due to 
potentially significant toxicities, including capillary leak syndrome. Low dose IL-2, on the 
other hand, is safe but not as effective at stimulating antitumor T cells (153). Another 
disadvantage to IL-2 treatment is that it promotes the expansion of Tregs, a T cell 
subset with inhibitory activities (154). The IFNα cytokine has pleiotropic effects on 
immune cells. It stimulates MHC I presentation, DC maturation, effector cell activation 
and it can induce tumor cell apoptosis. IFNα is approved for the treatment of multiple 
cancer types including leukemia, melanoma, Kaposi’s sarcoma and follicular Non-
Hodgkin’s lymphoma. It is less toxic than IL-2 but efficacy of IFNα treatment is 
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inconsistent (155). Other cytokines being tested preclinically are IL-12, IL-15, IL-18, IL-
7, IL-21, IL-23 and GM-CSF. IL-12 and IL-15 promote NK function, Th1 T cell 
differentiation and CD8 T cell activities (156-158). Both have shown promise in mouse 
studies, though IL-12 treatment in a clinical trial only saw one patient partially respond 
(158-160). IL-18 and IL-21 are two more NK and CD8 T cell promoting cytokines which 
have seen modest results in clinical trials (161,162). IL-7 is another promising cytokine 
important for T cell function. Multiple clinical trials determined that IL-7 expands the CD4 
and CD8 T cell populations without expanding Tregs and also has less toxicity 
compared to other cytokines (163). GM-CSF, on the other hand, is a highly pleiotropic 
cytokine that has proven a good adjuvant for antigen vaccination therapy (164,165).  
1.4.2 Checkpoint Blockade 
Checkpoint therapy has been the most therapeutically successful immunotherapy 
method to date. Checkpoint blockade aims to prevent or remove the suppression of T 
and NK cell activation by blocking co-inhibitory receptors on T and NK cells. The best 
results have been demonstrated for the blocking of CTLA-4 and PD-1, both co-inhibitory 
receptors expressed on activated T and NK cells. To date, one anti-CTLA-4 
(ipilimumab) and two anti-PD-1 (pembrolizumab and nivolumab) antibodies have been 
FDA approved (143,166). Interestingly, studies show that treatment with anti-CTLA-4 or 
anti-PD-1 antibody re-activates T cells and causes tumor regression, and these effects 
are synergized when patients were treated with both antibodies (167,168). The success 
of checkpoint blockade is primarily attributed to the reactivation of T cells, but some 
research shows that NK cell reactivation could contribute to tumor regression. In two 
studies, anti-PD-1 antibody treatment promotes NK cell cytotoxicity toward tumor 
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targets in vitro and prolongs survival in glioma tumor bearing mice (169,170). Other 
studies show that while anti-CTLA-4 treatment suppresses NK cell production of IFNγ in 
vitro, it promotes NK cell infiltration into the tumor microenvironment in mice (171,172). 
TIM-3 is another checkpoint receptor that is expressed on exhausted T cells and all NK 
cells. TIM-3 blockade on antigen specific CD8 T cells from patients enhances their 
cytokine secretion and proliferation and synergic effects are seen in combination with 
anti-PD-1 antibody (173). The function of TIM-3 on NK cells, however, is less clear and 
conflicting results have been reported on whether it acts in an activating or an inhibitory 
capacity (174). It is important to note that the success of CTLA-4 and PD-1 blockade is 
reliant on the immunogenicity of the tumor cells. Reactivated T cells are only cytotoxic 
to antigen expressing cells. Thus, checkpoint blockade is more effective at treating 
tumors which have a high mutation load, and thus express more neoantigens (143). The 
effects of checkpoint therapy, therefore, could be enhanced when used in combination 
with drugs that stimulate antigen expression or presentation. 
1.4.3 T Cell Therapy 
Improving T cell function has been the major focus of immunotherapy because T 
cells, especially CD8 T cells, are major effectors in the antitumor immune response. 
However, tumor infiltrated T cells are often repressed or unable to target antigen or 
MHC loss tumor cells. The challenge of enhancing the activity of T cells toward tumor 
cells has been approached in several ways, including through T cell adoptive cell 
transfer (ACT) and peptide vaccination. Both therapies utilize strategies which rely on T 
cells responding to known and unknown antigens.  
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All three types of tumor antigens are utilized in these therapies, dependent upon 
the tumor type. The use of TSAs is therapeutically appealing because the restricted 
nature of their expression prevents any cytotoxicity toward normal tissue. T cells 
specific for TSAs also have higher binding affinities than those specific for TAAs. TAAs 
are useful, however, because they are generally expressed by many patients of a single 
cancer type. The use of CTAs is also appealing due to their broad expression among 
individuals within a cancer type, or even across several cancer types (143). 
Autoimmunity is also not a complicating factor with CTAs because besides tumor cells, 
they are only expressed by the testis, which lacks MHC I expression (175).  
1.4.3.1 Adoptive Cell Transfer 
One approach to enhancing the T cell response is to treat the patient with 
activated T cells isolated from either the patient or a donor. The process of autologous T 
cell ACT consists of isolating T cells from a patient’s blood or from their surgically 
removed primary tumor, expanding and activating the T cells ex vivo, and transferring 
them back into the patient. ACT with allogeneic T cells is performed by isolating T cells 
from a patient in remission and transferring them into a patient who has the same type 
of cancer but is not in remission. Autologous ACT is much more commonly performed 
than allogeneic ACT. Both types of ACT are more effective when performed after 
radiation or chemotherapy induced lymphodepletion. This is advantageous because 
lymphodepletion removes the immunosuppressive immune cells so that the T cells are 
not transferred into an inhibitory environment (176). Tumor-specific T cells can also be 
selected for based on in vitro reactivity to autologous tumor cells. If selecting for a 
known antigen, antigen-specific T cells can be specifically expanded after repeated 
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stimulation with peptide pulsed APCs (177). ACT has proven most successful at treating 
melanoma, with a complete tumor regression rate of 20% (178). However, there are 
several factors which limit the applicability of T cell ACT. T cell ACT is expensive, 
difficult to standardize and has limited efficacy in patients. For example, a major limiting 
factor in ACT use is the difficulty of isolating and expanding antitumor T cells from most 
tumor types. Melanoma is so far the only tumor type from which T cells can consistently 
be successfully isolated (176). Another challenge with ACT using antigen-specific T 
cells is minimizing autoimmunity. This is especially true when using TAA-specific T cells 
as off tumor side effects are seen toward normal cells expressing the TAA (179). In one 
study, ACT of T cells enriched for specificity to three different melanoma TAAs was 
largely unsuccessful at inducing tumor regression and sometimes resulted in 
autoimmunity (180).  
Improving the antitumor cytolytic activity of adoptively transferred T cells was 
addressed by the development of T cells expressing a transgenic TCR. In this method, 
autologous T cells are transfected with cDNA encoding a TCR sequence. This 
sequence is designed to exhibit higher affinity to a known tumor antigen than the 
corresponding native TCR sequence (176). The main disadvantage to transgenic T 
(TCR-T) cells is enhanced off target reactivity. While TAA-specific TCR-T cells are more 
cytolytic toward TAA expressing tumor cells than nontransgenic T cells, they are also 
more reactive toward TAA expressing normal tissue and can induce off target 
autoimmunity, as evidenced by clinical trials with MART-1 and gp100 specific TCR-T 
cells (181). Unintentional cross-reactivity of a TCR-T cell with self antigens poses 
another source of off-target effects, as was the case with MAGE-A3 TCR-T cells (182). 
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In addition, the higher affinity of the TCR can cause potentially lethal toxicity (143,181). 
Like nontransgenic T cells, TCR-T cell recognition of antigen is HLA haplotype-
dependent, and thus their use is restricted to HLA-matched patients whose tumor cells 
also express the antigen of interest. Multiple clinical trials have determined that ACT 
with TCR-T cells can induce tumor regression and improve survival in the right setting. 
TCR-T cells against NY-ESO-1, MART-1, MAGE-A3 and gp100 are among those tested 
(181,183-186).  
Chimeric antigen receptor (CAR) T cells are T cells which are engineered to 
express an immunoglobulin-T cell receptor hybrid. The third generation CAR T cells 
used today express a fusion of an extracellular antibody domain that is specific to a 
tumor antigen, an intracellular ITAM signaling domain and a costimulatory molecule 
domain. The costimulatory domains were added to help promote T cell activation and 
prolong T cell survival in vivo. The major advantages to using CAR T cells are their high 
cytotoxicity toward targets and that they do not recognize antigen in the context of MHC, 
and can thus can be transferred into patients regardless of HLA haplotype. However, 
the downside of the high toxicity of CAR T cells toward cells expressing the target 
antigen is that lethal toxicity is a risk if the antigen is expressed by nontumor cells (187). 
Thus, the pool of antigens which can be targeted by CAR T cell therapy is restricted to 
TSAs. Also, because of their high cytotoxicity, the main toxicity involved in CAR T cell 
therapy in general is cytokine release syndrome (CRS). In CRS, activated CAR T cells 
release a high level of the cytokines TNF-α, IFNγ, IL-6, IL-2, IL-1 and IL-8 which can 
cause a range of symptoms, including vascular leak syndrome and death (188). Many 
clinical trials are ongoing to test the safety and efficacy of CAR T cells to several tumor 
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antigens, though it is clear that CAR T cells are much more effective at treating 
hematological malignancies than solid tumors (189). In fact, CD19 CAR T cell therapy is 
considered a breakthrough therapy due to its success in treating B cell malignancies 
(176,189).  
1.4.3.2 Vaccination 
The second approach to enhancing the antitumor T cell response is antigen or 
whole cell vaccination. The first step in vaccination is to identify antigens that are 
expressed by the tumor and elicit a CD8 T cell response. Multiple methods have been 
developed to identify such antigens, including Serologic Identification by Recombinant 
Expression Cloning (SEREX), cDNA library screening and sequencing followed by 
epitope prediction. This last method is the most clinically applicable method to quickly 
identify neoantigens in individual patients (143). It entails deep sequencing to identify 
mutations, computationally translating the mutations into proteins and inputting the 
predicted proteins into MHC I binding algorithms to identify MHC I binding epitopes 
(190).  
Vaccination methods that have been developed for cancer immunotherapy 
include vaccination with tumor cells, RNA, DNA, peptides plus adjuvants or APCs 
pulsed with tumor antigens. Vaccination with allogeneic tumor cells relies on the 
patient’s T cells to react to unknown tumor antigens expressed by the tumor cells. 
Canvaxin and Melcacine are two mixtures of melanoma lines with different HLA 
haplotypes that are currently being tested in clinical trials for melanoma. Canvaxin is 
also being tested with colon cancer, with the idea that colon cancer and melanoma 
share some tumor antigens (175). RNA vaccination is the second method which does 
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not necessitate the identification of antigens. For this strategy, total tumor RNA or 
mRNA is pulsed into autologous DCs, which are used for the vaccination. A phase I 
clinical trial with total renal RNA showed that RNA-transfected DCs stimulate renal 
tumor antigen specific CD8 T cell cells without inducing autoimmunity (191). DNA 
vaccination is a method being developed to attempt to elicit an immune response to a 
known antigen. In this case, cDNA of the gene of interest is cloned into an expression 
plasmid, which is then used for vaccination. APCs at the vaccination site take up the 
plasmid and present the epitope(s) to CD8 T cells, while the unmethylated bacterial 
DNA serves as an adjuvant. GM-CSF treatment has been shown to improve the efficacy 
of DNA vaccinations through promoting DC activity (192). However, DNA vaccination 
has failed to prove therapeutically beneficial so far. Peptide and protein can also be 
used for vaccination, either alone or pulsed into APCs. Peptide vaccination not only 
requires the identification of the antigen, but also that patients express the appropriate 
HLA allele on which the peptide is presented, which limits the applicability of this 
method. Protein vaccination, on the other hand, also requires the identification of the 
antigen, but is not restricted by HLA type. APCs can be pulsed with an individual 
protein/peptide that is known to form a tumor antigen, or with a cocktail of 
peptides/proteins that are specific to an individual patient’s tumor mutations. This 
strategy is the only vaccination method which has been FDA approved; sipuleucel-T is 
the use of autologous peripheral blood mononuclear cells (PBMC) pulsed with a 
recombinant fusion protein of prostatic acid phosphatase and GM-CSF to treat prostate 
cancer (193). Additionally, prolonged survival and expansion of TSA specific T cells 
have been reported in clinical trials using individual or pooled TSAs (194,195). 
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Vaccination with TAAs has, however, yielded disappointing results due to the limitations 
mentioned above (143). Peptides and proteins can also be directly vaccinated. 
However, since direct peptide and protein vaccination methods utilize an antigen(s) 
from a single protein, tumor resistance can be achieved by antigen loss tumor variants. 
Peptides/proteins tested in clinical trials include gp100, MAGE-A3 and NY-ESO-1 (192). 
In general, while vaccination as a monotherapy can stimulate an antigen-specific T cell 
response, the overall immune response is too weak to result in therapeutic benefit. 
There is hope that combination therapy as well as the identification of more 
immunogenic antigens will improve therapeutic responses to vaccination.  
1.4.4 NK Cell Therapy 
 Historically, the immune system was thought to play no role in influencing cancer 
growth because tumor studies using immunodeficient mouse models did not develop 
spontaneous tumors more frequently or exhibit reduced tumor growth over time 
compared to wildtype mice. These models, however, were not completely 
immunodeficient, and had functional NK cells, whose activity was providing that 
antitumor selection. Today, we know that NK cells are most effective against targeting 
hematological malignancies and metastases, and less efficient at infiltrating solid tumors 
(174).  
Several different therapeutic strategies have been developed in order to improve 
NK cell cytolytic activity toward tumors. One mechanism by which tumor cells suppress 
NK cell function is through the secretion of TGF-β, which is the main 
immunosuppressive cytokine that negatively regulates NK cell function. To prevent 
tumor secreted TGF-β from suppressing tumor infiltrating NK cells, multiple TGF-β 
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inhibitors have been developed with one, galunisertib, currently being tested in a clinical 
trial (196). However, as mentioned above, cytokines have pleiotropic effects and thus 
TGF-β inhibition has a high degree of toxicity (174). Another strategy to remove NK cell 
inhibition is to block the inhibitory NK receptors, and two monoclonal antibodies (mAb) 
are being tested in clinical trials that bind to and block signaling through the KIR2DL1-3 
(IPH2101) and NKG2A-CD94 (monalizumab) inhibitory receptors. Multiple approaches 
are also being developed to improve NK cell detection of tumor cells by the NK 
activating receptor CD16. First, mAb to tumor specific antigens (α-CD20, α-GD2, α-
Her2, α-EGFR) are FDA approved and commonly used in the clinic to promote tumor 
cell apoptosis. They bridge tumor cells and NK cells together by concurrently binding to 
tumor cell signaling receptors and to CD16 on NK cells, thereby inducing ADCC of 
tumor cells (174). Bispecific and trispecific killer cell engagers are being developed pre-
clinically as an alternative method to bridge together tumor antigens to CD16 on NK 
cells. Bispecific killer cell engagers are formed by fusing an Fv domain that binds to a 
tumor antigen with an Fv domain that binds CD16. Trispecific killer cell engagers 
contain a third Fv domain that binds to a different tumor antigen, the same tumor 
antigen or the IL-15 receptor (196). Two other NK activating receptors, NKG2D and 
NKp30, are promising targets in immunotherapy. In phase I and II clinical trials, treating 
melanoma and non-small-cell lung cancer patients with exosomes containing IL-15Rα 
and NKG2D or NKp30 ligands prolongs progression-free survival (197,198).  
Compared to CD8 T cells, NK cell ACT is in the early stages of development and 
clinical testing. NK ACT methods include adoptive transfer of autologous (from the 
patient) or allogeneic (from a donor) NK cells with none, short term or long term ex vivo 
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expansion and either IL-2, IL-15 or IL-18 treatment to maintain NK cell activation. The 
NK cell adoptive transfer method most tested in clinical trials is the use of short term ex 
vivo expanded allogeneic NK cells with systemic IL-2 treatment. The use of allogeneic 
NK cells is advantageous to autologous NK cells because cancer patients often have 
impaired NK cell functions which cannot be overcome by ex vivo expansion and 
activation (199). Autologous NK cells are also more inhibited by MHC expressing tumor 
cells due to inhibitory receptor matching. Indeed, adoptive transfer of autologous NK 
cells does not affect tumor growth in patients with metastatic melanoma or renal cell 
carcinoma (200). Adoptive transfer with haploidentical allogeneic NK cells, however, 
induces tumor regression and remission in patients with acute myeloid leukemia by 
targeting MHC-loss tumor cells (201,202). Haploidentical allogeneic NK cells are able to 
kill MHC mismatched tumor cells, and are therefore not dependent on tumor MHC loss 
for activity. As for cytokine treatment, IL-2 was found to activate Tregs as well as NK 
cells, making it less than ideal for use with NK ACT. Other cytokines that have been 
explored to replace IL-2 are IL-12, IL-15 and IL-21. IL-15 has emerged as the best 
cytokine for specifically improving NK cell function in vivo (174). Like with T cells, 
genetic modification of adoptively transferred NK cells is being explored to improve 
antitumor NK cell cytotoxicity. CD19-specific CAR NK cells show promise by enhancing 
adoptively transferred NK cell cytotoxicity against B cell malignancies in mice and 
clinical trials are currently underway to determine if there is therapeutic advantage with 
CAR NK cell treatment (203). The human NK cell line NK-92 is another source of donor 
NK cells. NK-92 cells lack expression of the inhibitory receptors and are highly cytotoxic 
to many tumor types in vitro, but not to healthy allogeneic cells (204). The use of NK-92 
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cells is advantageous to primary NK cells because they are immortalized, and therefore 
have unlimited expansion potential. The use of a cell line also eliminates all sources of 
variability originating from isolating and expanding NK cells from individual donors, thus 
yielding more reproducible results (205). Importantly, phase I clinical trials determined 
that transferred irradiated NK-92 cells do not develop into a tumor themselves and the 
body does not develop HLA antibodies in response to injected NK-92 cells (204,206). 
Overall, while several completed phase I clinical trials show that the discussed methods 
of NK cell adoptive therapy are safe and do not induce graft vs. host disease, it remains 
to be seen whether adoptive therapy of NK cells has therapeutic benefit.  
1.4.5 Invariant NKT Cell Therapy 
 Invariant NKT (iNKT) cells are a small population of DN T cells that express an 
antigen-specific TCR, but instead recognize targets expressing lipid antigens presented 
by the nonclassical MHC molecule CD1d (207). In tumor immunity, iNKT mainly function 
by influencing other immune cells through cytokine secretion. iNKT cells produce IFNγ 
and IL-12, which promote Th1 differentiation and NK cell activation. iNKT knockout (KO) 
and adoptive transfer experiments show that iNKT cells are important for tumor 
protection (208,209). iNKT cells can also directly kill tumor cells expressing CD1d, 
though most tumor cells do not express this molecule (210). αGalCer, an iNKT agonist 
which activates iNKT cells, is the only NKT targeting immunotherapy. Multiple studies 
show that αGalCer treatment effectively protects against tumors and metastases in mice 
(211,212). Clinical trials have shown αGalCer treatment to be safe, though whether or 
not improving iNKT activity will be therapeutically beneficial still remains to be 
determined (207,213). 
44 
 
1.4.6 Radiotherapy and Chemotherapy 
 Radiotherapy and chemotherapies are often used in combination therapy with 
immunotherapies. This is because they not only directly kill cancer cells, but can also 
enhance tumor cell immunogenicity or improve the activity of immune cells. In fact, 
radiotherapy depends on the immune system for efficacy in treating tumors; mouse 
studies revealed that radiotherapy induces tumor regression in immunocompetent mice, 
but not in mice lacking T cells (214). There are two mechanisms by which radiotherapy 
and chemotherapies enhance the immune response to tumors: through immunogenic 
cell death or through the regulation of specific genes involved in tumor cell 
immunogenicity. 
Radiotherapy or chemotherapy induced immunogenic cell death is the process 
by which inflammatory molecules like cytokines, chemokines, antigens and DAMPs are 
released upon cell death. The cytokines and chemokines attract immune cells like DCs, 
CD8 T cells, macrophages, Tregs and MDSCs to the tumor. The released tumor 
antigens and DAMPs activate the infiltrated DCs and NK cells. A DNA damage 
response is induced following irradiation or chemotherapy (cytarabine, cisplantin, 5-
fluorouracil or bortezomib) treatment, which upregulates the expression of NKG2D 
receptor ligands on tumor cells, further promoting NK cell activation (215,216). Activated 
DCs migrate to the draining lymph node, where they prime T cells and promote CD8 T 
cell infiltration into the tumor microenvironment (217). Radiotherapy also activates type I 
IFN expression, which promotes DC activation and further attracts CD8 T cells to the 
tumor. However, prolonged type I IFN signaling promotes tumor cell survival 
mechanisms (217). In addition, radiotherapy recruits two pro-tumor immune cell types- 
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Tregs and MDSCs. Radiotherapy induced recruitment of MDSCs, however, is 
temporary and ultimately reversed (218). Tregs are not only recruited as a result of 
radiotherapy induced immunogenic cell death, but radiotherapy also promotes Treg 
expansion and function in the tumor microenvironment (219).  
In addition to immunogenic cell death, there are a number of mechanisms by 
which radiotherapy and chemotherapy promote tumor cell immunogenicity. First, 
radiotherapy and high dose cyclophosphamide (CPA) temporarily induce lymphopaenia. 
Temporary lymphopaenia ultimately enhances the antitumor response because all the 
immunosuppressive immune cells are depleted. It is then possible for the reconstituted 
lymphoid cells to overcome tumor induced immunosuppression (220). Radiotherapy and 
5-aza-2’-deoxycitidine (DAC) specifically enhance CD8 T cell activity by upregulating 
MHC molecule or CTA expression, which expand the repertoire of antigens in tumor 
cells (221,222). Irradiation also increases the pool of antigens by promoting protein 
degradation, by stimulating mTOR-dependent protein production, and by inducing the 
expression of previously unexpressed proteins (223). Paclitaxel, doxorubicin and 
methotrexate can stimulate DC expression of antigen processing genes and antigen 
presentation to T cells (224). In addition, paclitaxel, cisplatin and doxorubicin stimulate 
Man-6-P upregulation, rendering tumor cells more sensitive to Granzyme B (215). 
Radiotherapy upregulates FAS expression and DAC treatment restores sensitivity to 
apoptosis by reversing death-associated protein kinase (DAPK) hypermethylation 
(223,225). 5,6-dimethylxanthenone-4-acetic acid (DMXAA) has several effects on the 
antitumor immune response, including enhancing CD4 T cell, macrophage and NK cell 
activities and promoting CD8 T cell infiltration into the tumor microenvironment (223). 
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Doxorubicin treatment enriches tumor associated macrophage populations and 
stimulates tumor infiltrated T cell proliferation (226,227). Paclitaxel promotes Th1 
responses and suppresses Treg cytokine production (215). Drugs which enhance NK 
antitumor activities include lenalidomide, which increases the number of NK cells in the 
periphery and imatinib mesylate, which promotes DC-dependent NK cell activation and 
IFNγ production (174,228). Interestingly, imatinib mesylate also induces the expansion 
of IFN-producing killer DCs (IKDCs). IKDCs have properties of NK cells and DCs but 
can also lyse target cells and secrete IFNγ and have been shown to have antitumor 
functions in vivo (229). Immunosuppressive immune cells can be depleted by multiple 
chemotherapies. Gemcitabine and ranitidine deplete MDSCs, and T cell reactivation 
following MDSC depletion can effectively induce tumor regression (230,231). 
Gemcitabine also depletes Tregs and B cells and suppresses antibody production, 
though B cell depletion does not affect tumor growth (230,232). Low dose CPA depletes 
and inhibits Tregs by suppressing FOXP3 and GITR expression (233). 
Because radiotherapy and chemotherapy stimulate an antitumor immune 
response, these treatments are ideal for combination therapy with immunotherapies. 
Indeed, radiotherapy combined with PD-1 or CTLA-4 checkpoint blockade have had 
major successes in the clinic (217). Lymphopaenia combined with CD8 T cell adoptive 
cell therapy has also shown great promise in a clinical trial (234). Gemcitabine in 
combination with cytokine treatment or vaccination increased the number of tumor 
antigen-specific CD8 T cells in tumors in other trials (223). 
 
1.4.7 Conclusion 
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 While immunotherapy has had major success at treating a subset of patients with 
specific cancer types, most solid tumor types are poorly responsive to immunotherapy 
treatment due to difficulty of tumor infiltration and poor tumor cell immunogenicity. 
Additionally, while these methods show promising results in mice, few of them have 
reproducibly induced therapeutic benefit in phase II clinical trials. Like with any cancer 
treatment, combination therapy targeting complementary aspects of the tumor 
immunoediting process is likely to enhance the antitumor effects of individual 
immunotherapies. New targets must be identified, therefore, in order to maximize the 
promising potential of combinatorial immunotherapy treatment. 
Section 1.5: Epigenetics as a Target in Cancer Therapy  
Tumor cells frequently downregulate MHC molecules, antigen processing genes 
and NK receptor ligands to avoid detection by immune cells. In order to enhance tumor 
immunogenicity, these changes in gene expression must be corrected. Several 
approaches have been proposed to correct abnormal gene expression in tumors. First, 
by changing the DNA sequence, one can attempt to correct abnormal gene expression 
(235). Correcting DNA sequences in a patient’s tumor cells is certainly plausible but is 
not yet a practical approach to correcting abnormal gene expression. Alternatively, 
abnormal gene expression can be corrected by altering any one of several 
posttranslational modifications found on the chromatin of tumor cells that are important 
for gene expression (236). In contrast to genetic regulatory mechanisms that are stable, 
posttranslational modifications on chromatin are dynamic, and in theory, reversible. 
Because posttranslational modifications on chromatin are required for regulating pro-
cancer gene expression in tumor cells, do not change the DNA sequence, are in theory 
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reversible, and are established by the actions of enzymes, this makes them attractive 
targets to correct abnormal gene expression as a means of therapy.  
Targeting epigenetic regulators for the treatment of human cancers has proved 
successful for histone deacetylases (HDAC) and DNA methyltransferases (DNMT). In 
each case, the therapeutics developed are approved for difficult to treat cancers, 
providing valuable assets to oncologists (237,238). Examples include: vorinostat and 
romidepsin, FDA-approved HDAC inhibitors (HDACi) used to treat cutaneous T cell 
lymphoma, and azacitidine and decitabine, FDA-approved DNMT inhibitors (DNMTi) for 
the treatment of myelodysplastic syndromes (239,240). Next generation, more specific 
HDAC and DNMT inhibitors are currently being developed to improve on these 
successes. Because of these successes, many other small molecules are actively being 
pursued which target posttranslational modifications on chromatin for therapeutic 
benefit. These drugs primarily target a large number of histone modifying enzymes and 
small RNA regulatory pathways. Histone modifying enzymes currently being targeted 
include deacetylases, acetyltransferases and demethylases. In some cases, small 
molecules targeting these regulators have made it into Phase II clinical trials 
(236,237,239,240). These molecules are tested alone and in combination 
chemotherapy and include HDAC inhibitors (entinostat, mocetinostat, panobinostat, 
bellinostat, valproic acid, givinostat, CHR-3996, CHR-2845, and SB939), the KDM1A 
demethylase inhibitor tranylcypromine, and the HAT inhibitor curcumin 
(236,237,239,240). Phase II trials revealed promising results for mocetinostat and 
bellinostat. 
Section 1.6: Epigenetics in Cancer Biology 
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 Childhood cancers have the highest mutation load in epigenetic machinery. 
However, mutations or changes in expression of epigenetic modifiers occur in a broad 
range of tumor types. Alterations in DNA methylation is most common in haematological 
malignancies and is due to frequent mutations in DNA methyltransferases and 
methylcytosine dioxygenase enzymes like DNMT3A, DNMT1, TET1, TET2, TET3, 
MBD1 and MBD3 (241). DNMT3A and TET2 mutations are common in lymphomas and 
leukemias and are correlated with poor prognosis (241-244). Changes in DNA 
methylation patterns induced by DNMT3A and TET2 mutations promote the biology of 
cancer stem cells (241). Additionally, a common phenomenon in cancer is global DNA 
hypomethylation and promoter CpG hypermethylation. Alterations in histone 
modifications are also typical in many tumor types, hematological and solid. For 
example, EZH2, a histone methyltransferase enzyme, exhibits both gain of function and 
loss of function mutations, depending on cancer type, which leads to either hyper- or 
hypo- histone methylation, respectively. Mutations in another histone methyltransferase 
MLL2 causes elevated levels of repressive H3K27me3 in non-Hodgkin lymphomas 
(245,246). SETD2 mutation is correlated with poor prognosis in renal cell carcinoma 
(247). Mutations in the histone acetyltransferase CBP/p300 affect tumor cell 
proliferation and DNA stability (248). Other histone modifiers mutated in cancer include 
MLL, MLL3, MLL4, SETD1A, PRDM9, NSD1, NSD2, KDM5C, KDM6A, KDM2B, EP300, 
HDAC2, HDAC4, and HDAC9 (241). 
Section 1.7: Epigenetics 
Chromatin is composed of nucleosomes, which in turn are composed of two 
copies of each of the canonical histones H2A, H2B, H3, and H4 wrapped by ~150 bp of 
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DNA (249). Nucleosomes are positioned along DNA in a “beads on a string” 
configuration to create a 10-nm fiber that through internucleosome contacts creates a 
variety of higher ordered chromatin structures, including a molten globule with short 
stretches of a 30-nm fiber (250,251). 
In most cases, the highly compacted chromatin structure limits DNA accessibility, 
and therefore must be modified to promote essential nuclear processes like 
transcription, DNA replication, and DNA repair (252). In higher eukaryotes, 
posttranslational modification regulates the function of chromatin. These diverse post-
translational modifications are commonly, but not accurately, referred to as epigenetic 
regulatory mechanisms (253). Posttranslational modifications to chromatin do not 
change the DNA sequence but rather are deposited onto chromatin by enzyme 
catalyzed reactions (254). These modifications include histone posttranslational 
modifications, DNA methylation, incorporation of histone variants, and chromatin 
remodeling (254). These alterations arise and are subsequently maintained on 
chromatin through interactions between the enzymes that deposit them and sequence-
specific DNA-binding factors (255). 
1.7.1 Histone Modifications 
The posttranslational modification of histones occurs by histone modifying 
enzymes. And just as histones can be modified, the modifications can be removed by 
de-modifying enzymes. Histones are primarily modified on the N-terminal and C-
terminal ends, but can also be modified throughout their sequence (255). Histone 
modifications alter chromatin structure or recruit additional chromatin-modifying 
complexes, which in turn regulate nuclear processes like transcription. Common 
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modifications include acetylation, methylation, and phosphorylation. Histone 
modifications are usually found in combinations in chromatin (e.g., H3K9me1 with 
H3K4me3) so as to provide redundancy in their ability to direct nuclear processes (256). 
1.7.2 Histone Variants 
To similar effect, the incorporation of histone variants serves to alter chromatin 
structure and stability, and it provides unique contact surfaces for the recruitment of 
chromatin-modifying complexes (257). The incorporation of histone variants can occur 
through both ATP-dependent and ATP-independent mechanisms. ATP-independent 
mechanisms include histone chaperones dedicated to the deposition of specific histone 
variants. Histone chaperones support replication dependent (coupled with DNA 
replication during S-phase) and independent (outside S-phase) histone deposition 
pathways. Examples include the ATRX/DAXX pathway for the deposition of histone 
H3.3 and the HJURP pathway for the deposition of CENP-A (257). 
1.7.3 DNA Methylation 
Just like histones, DNA can be modified to provide a stable method of regulating 
gene expression. In mammals, modifications to DNA usually occur on CpG 
dinucleotides, but they have also been observed outside of this context (258,259). The 
most common modification to CpG dinucleotides is the methylation of the fifth carbon of 
cytosine (5mC), catalyzed by the DNMT family of enzymes. 5mC is removed by both 
passive and active means, the latter including the TET family of enzymes and to a 
lesser extent APOBEC (260). DNA methylation largely represses gene expression by 
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altering nucleosome positioning and stability and by recruiting chromatin-modifying 
complexes containing subunits that bind methylated DNA (261,262). 
1.7.4 Chromatin Remodeling Complexes 
Chromatin remodeling is the process whereby the position, occupancy, or the 
histone composition of a nucleosome is altered in the chromatin. These activities occur 
by both ATP-dependent and ATP-independent mechanisms (263). ATP-independent 
mechanisms can occur from transcription factors shifting the position of nucleosomes as 
a consequence of DNA binding, or by the action of histone chaperones, depositing or 
removing histones from chromatin (264,265). In contrast to ATP-independent 
mechanisms, ATP-dependent mechanisms are enzymatic and constitute the majority of 
the remodeling activity in the cell (266). These activities are usually catalyzed by 
multisubunit ATP-dependent chromatin remodeling complexes which are organized into 
SWI/SNF, ISWI, CHD, and INO80 families based on the sequence homology of the 
incorporated ATPase (267). Each family of ATPase catalyzes distinct remodeling 
activities: incremental nucleosome sliding on DNA in cis, the creation of DNA loops on 
the surface of the nucleosome, eviction of histone H2A/H2B dimers, eviction of the 
histone octamer, or the exchange of histone octamer subunits within the nucleosome to 
change its composition. Each of these activities alters the accessibility of DNA in the 
chromatin to DNA-binding factors, which in turn regulates essential nuclear processes 
like transcription, DNA replication, and DNA repair. 
Complexes in the SWI/SNF family include the large multisubunit BAF, PBAF, and 
WINAC complexes, which function as coregulators of transcription and in aiding of the 
repair of DNA damage (268). Remodeling reactions catalyzed by SWI/SNF family 
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members include simple nucleosome sliding reactions, but they can catalyze more 
dramatic reactions, like creating DNA loops on the surface of nucleosomes or the 
eviction of H2A/H2B dimers from the nucleosome structure (269).  
Like SWI/SNF, the members of the INO80 family of complexes are also large 
multisubunit complexes which regulate transcription, but they have more prominent 
functions in DNA damage repair (270). These complexes, including SCRAP, Tip60/p400 
and INO80, are unique among ATP-dependent remodeling complexes because they 
can catalyze the exchange of histones in the nucleosome (271-275).  
The CHD family contains nine different ATPases, the most numerous of the 
remodeling families (276). The best characterized complex in this family is NURD, 
which contains both ATP-dependent chromatin remodeling and histone deacetylase 
activities (277). The MBD2-NURD complex can bind 5mC DNA and promote the 
repression of genes through its remodeling and histone deacetylase activities and the 
MBD3-NURD complex functions as an activator of transcription (278,279). In addition, a 
NURD-like complex containing CHD5 has been identified in the brain and acts as a 
coregulator of transcription (280). However, most of the complexes containing other 
CHD ATPases await characterization.  
As opposed to the large SWI/SNF, INO80, and CHD complexes, most ISWI 
complexes are comparatively small, consisting of only two or three subunits (281). At a 
minimum, each of these complexes contains a single large subunit with several histone-
binding domains (including PHD and bromodomains) and an ISWI family ATPase. ISWI 
family chromatin remodeling complexes catalyze the sliding of nucleosomes in short 
increments without DNA looping, histone exchange, or nucleosome displacement. 
54 
 
These complexes have diverse functions including the spacing of nucleosomes after 
DNA replication (CHRAC, ACF), RNA polymerase elongation (RSF), serving as 
coregulators of transcription (CERF, NURF, NoRC, b-WICH), and regulating DNA 
damage repair (WICH) (282-289). 
Recruitment of nucleosome remodeling complexes commonly occurs through 
direct interactions with transcription factors, histone modifications, and DNA sequences 
(290). Domains found in nucleosome remodeling complex subunits that recognize 
specific histone modifications include a variety of well-characterized plant homeodomain 
(PHD), chromo, and bromodomains, among others. The incorporation of individual 
subunits into chromatin remodeling complexes varies based on cell type expression, 
thus providing a means to generate distinct complexes with unique interaction surfaces 
(291). 
The biological functions of chromatin remodeling complexes during normal 
development have been extensively studied using mouse models (291). As expected, 
the subunits of many chromatin remodeling complexes have essential functions during 
mammalian development. However, because subunits of chromatin remodeling 
complexes are often found in multiple chromatin-associated complexes, understanding 
how specific chromatin remodeling complexes function during development has 
remained a challenge. As such, the deletion of a single subunit likely compromises 
several complexes resulting in pleiotropic effects. In somewhat of a surprise, several 
ATPases are not essential for the cell: SWI/SNF family members BRG1 and BRM, CHD 
family member CHD4, and ISWI family member SNF2L (292-295). The importance of 
chromatin remodeling complexes for development, but not necessarily for cell viability, 
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suggests that their mutation can result in a viable cell with abnormal developmental 
pathways. Because deregulated developmental pathways are known to contribute to the 
transition to cancer, it is likely that the mutation of subunits in chromatin remodeling 
complexes could contribute to cancer-related phenotypes (1,236). 
1.7.4.1 Chromatin Remodeling Complexes in Cancer Biology 
Chromatin remodeling complexes are known to be mutated and deregulated in 
expression in a variety of cancer types. As an exercise to quantify the mutation 
frequency for each chromatin remodeling complex subunit from a wide array of tumors, 
we mined the COSMIC database of somatic mutations in human cancers (296). 
Consistent with what was published by others, we observed that subunits of the 
SWI/SNF family of remodeling complexes are the most prominently mutated of the 
chromatin remodeling complex families (Fig. 1.1)(Table 1.1) (297,298). Mutations in the 
INI1 (also known as SNF5) and ARID1A (also known as BAF250A) components are 
frequently observed in tumors from diverse tissues including central nervous system, 
stomach, large intestine, bone, endometrium, liver, soft tissue, ovary, and urinary tract. 
Additional SWI/SNF subunits include the BRG1 ATPase, which is frequently mutated in 
tumors from ganglia and to a lesser extent the esophagus, large intestine, lung, and 
urinary tract. The PBAF-specific BAF180 (also known as PBRM1) and ARID2 subunits 
are frequently mutated in kidney cancer and to a lesser extent in a variety of tumors 
from the skin, esophagus, large intestine, cervix, liver, and lung. Interestingly, several of 
the relatively uncharacterized CHD ATPases were found modestly mutated in a variety 
of cancers including the stomach, large intestine, cervix, endometrium, lung, and urinary 
tract. 
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In addition to somatic mutation rates, the abnormal expression of genes in 
cancers can indicate roles in tumor development. Toward this end, we surveyed 
genomewide expression datasets from primary tumors using ONCOMINE to determine 
the frequency of deregulation for each subunit for chromatin remodeling complexes 
(Fig. 1.2; Table 1.2) (299). Consistent with their frequent somatic mutation in tumor 
samples, SWI/SNF family members are frequently deregulated in expression in tumors, 
thus underscoring their likely importance to cancer biology. The BRG1 ATPase, 
BAF155, BAF53A, and INI1 are overexpressed in a variety of tumor types including 
bladder, liver, ovarian, melanoma, leukemia, and myeloma cancers. In addition to the 
prominent representation of SWI/SNF subunits, subunits from the ISWI, CHD, and 
INO80 complexes are also deregulated. Subunits of the INO80 family of chromatin 
remodeling complexes including BAF53A, RUVBL1, and RUVBL2 subunits are 
overexpressed in bladder, cervix, myeloma, colon, and ovarian cancers. The NURD 
subunits MTA1 (but not MTA2 or 3), HDAC 1 and 2, and pRBAP48 are modestly 
deregulated in cervix, pancreatic, leukemia, colon, and esophagus cancers. Compared 
to the other families of remodeling complexes, the ISWI families are only modestly 
deregulated in cancers including overexpression in head, cervix, and kidney cancers. In 
support of these genome-wide analyses, independent reports in the literature have 
accumulated for several decades and have been used to establish correlative (germline 
and somatic mutation, deregulated expression, copy number changes), causative 
(mouse models), and mechanistic (physical and functional connections to cancer 
relevant pathways) connections between chromatin remodeling complexes and 
cancers.  
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BRG1, a catalytic ATPase of the SWI/SNF family, has well-characterized roles in 
regulating several tumor suppressor and oncogene pathways, including regulating cell 
cycle arrest, metastasis and p53-dependent regulation of DNA damage (300-304). 
Further, mouse models have demonstrated that tumor incidences are increased in 
heterozygous BRG1 KO mice (305). The use of mouse models has presented strong 
evidence that INI1 is a tumor suppressor. As in humans, mice heterozygous for INI1 
develop sarcomas closely resembling the human malignant rhabdoid tumors (306,307). 
The SWI/SNF subunit ARID1A (also known as BAF250A) is frequently mutated in 
several types of human cancer. In some tumor types, AIRID1A is the most frequently 
mutated gene (308,309). BAF180 has been shown to act as a tumor suppressor 
through functioning to inhibit the cell cycle and promote senescence (310,311). Possibly 
as a result of its interactions with p53, BAF180 has also been shown to regulate 
genome stability through functions in regulating DNA damage repair (312). BAF57 
truncation mutations found in human cancers were shown to lead to artificially elevated 
ER- and androgen receptor (AR)-regulated gene expression and provide a plausible 
molecular mechanism for their functions in regulating prostate and breast cancer cell 
biology (313).  
The Tip60/p400 subunit TRRAP of the INO80 family is an essential factor for 
MYC transformation activity and through interaction with acetylated p53, it is essential 
for p53 regulation of gene expression (314-316). Another INO80 subunit, RUVBL1, is 
also necessary for transformation by E1A, β-catenin, and MYC (317-319).  
The CHD4 subunit interacts with EGR1, which regulates cell growth, 
differentiation and apoptosis in prostate cancer and with ZIP, which is a transcriptional 
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repressor of genes involved in cell proliferation, survival, and migration (320,321). 
Similar to the INO80 complex subunits, MTA1 is required for MYC-induced 
transformation (322). MTA1 also interacts with the BCL11B repressor in T cell leukemia 
cells and ERα in breast cancer cells to regulate gene expression (323,324). Genes 
important to metastasis are also known targets of MTA1 regulatory activity. MTA1, 
recruited to the E-cadherin and BRCA1 promoters, silences the genes and in doing so 
promotes metastasis (325,326). Knockdown (KD) of HDAC1 and HDAC2 in several 
human cancer cell lines results in upregulation of p21 followed by cell cycle arrest both 
in tissue culture and in xenograft tumor models (327). MBD2 has important functions in 
the development of cancers through its ability to recruit the coregulatory activities of the 
NURD complex to the hypermethylated promoters of tumor suppressor genes (328-
333). When the NURD and NURF subunit RBAP46 is overexpressed in breast cancer 
cell lines both colony formation in vitro and tumor growth in mice is suppressed (334). 
CHD5 was found to be one among several tumor suppressor genes found on 
chromosome 1q36, which is the most common deletion found in a variety of human 
cancers, most prominently cancers of the CNS, hematopoietic system, and epithelium 
(thyroid, colon, cervix, and breast) (335).  
RSF1 of the ISWI family is located on chromosome 11q13.5, which is frequently 
duplicated in human tumors. In oral squamous cell cancers, RSF1 was found to be 
overexpressed relative to normal tissue, which correlates with decreased survival (336). 
In addition, a short hairpin RNA (shRNA) KD screen showed that the RSF1 gene 
located in the duplicated region is essential for paclitaxel resistance (337).  
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1.7.4.2 Chromatin Remodeling Complexes as a Target in Cancer Therapy 
The discovery that chromatin remodeling complexes regulate gene expression 
important for cancer progression has stimulated interest in screening them for small 
molecule regulators. Using completely different approaches, two successful screens 
have been performed for the BRG1 and RUVBL1 ATPases (338,339). To discover small 
molecule regulators of BRG1, a live cell screen was performed by measuring the 
expression of Bmi, a known target of BRG1 in embryonic stem cells, by high-throughput 
qRT-PCR. Follow-up assays were performed using embryonic stem cell lines with a 
knock-in Bmi-luciferase reporter allele. Several compounds were discovered with this 
approach and are being investigated further. In contrast to the live cell approach used 
for BRG1, a structure-based biochemical screen was performed to discover small 
molecule regulators for the RUVBL1 ATPase. To identify inhibitors of the RUVBL1 
ATPase activity, the authors used its known structure to model molecules from several 
libraries to the ATP-binding site. Promising compounds that could bind the ATP-binding 
site were assayed for the ability to inhibit a DNA-dependent ATPase activity for 
recombinant RUVBL1. This approach yielded several compounds, some of which 
inhibited the proliferation of cancer cells. 
In addition to discovering small molecules targeting the ATPase activity, as was 
performed for RUVBL1, resources can be invested to discover molecules to inhibit key 
protein–protein interactions essential for the function of chromatin remodeling 
complexes. The inhibition of the BAF57–AR interaction is a successful example of this 
strategy. BAF57 is known to physically interact with AR, and is required for AR binding 
to chromatin and AR-regulated gene expression in prostate cancer cells. The ectopic 
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expression of a peptide mimic to the sequence on BAF57 that interacts with AR resulted 
in inhibited AR binding to chromatin, reduced AR-stimulated transcription, and inhibited 
AR-dependent prostate cancer cell proliferation (340). These results are consistent with 
the possibility that the peptide is inhibiting the BAF57–AR interaction surface and 
preventing BAF57-dependent AR binding and transactivation. Additional means to 
inhibit chromatin remodeling complexes with this approach can also include targeting 
essential subunit interactions within a remodeling complex. While this approach benefits 
from the focus of a structure-based design, it will suffer from the difficulty of delivering 
peptides to intracellular targets in a patient’s tumor. 
Another strategy to therapeutically regulate chromatin remodeling is to identify 
small molecules that can regulate the expression of genes encoding essential subunits 
of chromatin remodeling complexes. This has successfully been done to re-express the 
BRM ATPase in cancer cell lines that have silenced its expression without a deletion 
(341,342). This screen used a glucocorticoid receptor-regulated luciferase reporter that 
is induced in the presence of BRM. As a result of this screen, two compounds were 
identified which increased the expression of BRM, inducing the expression of BRM 
target genes, and decreased the growth of cancer cell lines. Each of these compounds 
regulates BRM expression through an unknown mechanism. Additionally, 19fluorine 
nuclear magnetic resonance (19F NMR) small molecule screening identified an inhibitor 
to the NURF subunit BPTF, AU1 (343). 
1.7.4.3 The NURF Complex 
 The nucleosome remodeling factor (NURF) is the founding member of ISWI 
family of chromatin remodelers. It was first identified in Drosophila melanogaster and 
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subsequent purification human cells revealed that NURF is conserved across species 
(286,344). Mammalian NURF is composed of three subunits: SWI/SNF related, matrix 
associated, actin dependent regulator of chromatin, subfamily a, member 1 (SNF2L) or 
member 5 (SNF2H), RB binding protein 4, chromatin remodeling factor (pRBAP46/48) 
and bromodomain containing phd finger transcription factor (BPTF) (Fig. 1.3). SNF2L/H 
is the catalytic ATPase domain, which is also incorporated into the RSF1 and CERF 
complexes. It contains the C-terminal HAND, SANT and SLIDE domains, which interact 
with unmodified histone H4 N-terminal tails and linker DNA (345). Mammalian NURF 
preferentially incorporates SNF2L over SNF2H. The pRBAP46/48 proteins are 
members of a family of WD repeat proteins, proteins which have a highly conserved 
propeller-like structure. Besides NURF, the pRBAP46/48 subunit is also incorporated 
into the NURD and NURD-like complexes (346). BPTF is the largest subunit in the 
NURF complex and is both unique to the NURF complex and essential for NURF 
remodeling activity (286). BPTF contains several domains including a bromodomain, 
two PHD domains, a high mobility group (HMGA) domain, three LXXLL putative nuclear 
receptor-binding motifs, a DNA binding homeobox and different transcription factors 
(DDT) domain and a polyglutamate region (Fig 1.4). The functions of most of these 
domains have been characterized, and thus aid in our understanding of NURF 
recruitment to and interaction with chromatin. The HMGA domain contains an acidic 
patch which associates with nucleosomes and the C-terminal PHD2 and bromodomain 
motifs recognize the histone modifications H3K4me2/3 and H4K16, respectively (347-
349). These modifications are enriched at the transcription start site of transcriptionally 
active genes. The LXXLL motifs are important for interacting with other proteins and the 
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DDT domain likely interacts with DNA (345). In the mouse, BPTF is most highly 
expressed in the testis, spleen, brain and kidney tissues, with expression significantly 
declining after birth (286,350).NURF’s remodeling activities are restricted to sliding 
nucleosomes bi-directionally in 10 bp increments with minimal unwrapping of DNA from 
the nucleosome.  
NURF is recruited to chromatin by a combination of histone modifications, 
histone variants and transcription factors. While several remodeling complexes have 
conserved functions across cell types, NURF is a cell type-specific regulator of 
chromatin, likely through interaction with transcription factors that are cell type-restricted 
in expression (351). NURF’s interaction partners have been best characterized in 
Drosophila melanogaster, where it is known to interact with a variety of transcription 
factors including heat shock factor (HSF), GAGA, VP16, TRF2, TAF4b and PR 
(352,353). Mammalian NURF interacts with the SMAD2, SRF, AP-1, PR, USF1, MAZ 
and KEAP1 transcription factors, among others (345). NURF also interacts with another 
broad regulator of chromatin structure, CCCTC-binding factor (CTCF). CTCF interacts 
with cohesin to create loops in chromatin, allowing distal regulatory elements to regulate 
their target genes. NURF was shown to both localize to CTCF binding sites in chromatin 
and to interact with CTCF itself (351). NURF also preferentially remodels nucleosomes 
incorporating the H2A.Z histone variant, which is enriched at regulatory elements and 
transcription start sites of active genes (354). It is also possible that NURF binds to 
specific DNA sequences, though a consensus sequence has yet to be identified. 
NURF has essential functions in mouse embryogenesis but is not essential for 
adult cell viability (350,355). BPTF KO mice are embryonically lethal due to crucial 
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functions for BPTF in regulating the formation of the distal visceral endoderm through 
coregulation of Smad signaling (350). Critical functions for BPTF have also been shown 
in the ecotplacental cone during trophoblast differentiation and BPTF KO mice fail to 
gastrulate (356). In addition, several groups found that NURF regulates homeobox gene 
expression in embryonic stem cells (286,350,357). Multiple functions for BPTF have 
been identified in the adult mouse, including in thymocyte, erythrocyte and melanocyte 
differentiation, and oocyte development. A conditional BPTF KO study discovered that 
thymocytes fail to differentiate beyond the SP state into DP thymocytes without NURF 
activity. The thymocyte differentiation genes Egr1, AP-1 and SRF were identified as a 
BPTF regulated by either gene expression or protein function (355). In erythroid cells 
NURF is enriched at promoters of erythroid genes and NURF binding is associated with 
open chromatin and gene expression during erythroid differentiation (358). In adult 
melanocyte stem cells, BPTF and microphthalmia-associated transcription factor (MITF) 
coregulate genes important for melanocyte differentiation and BPTF KD results in 
transcriptional repression of these genes and defects in differentiation into melanocytes 
(359). In addition, NURF interaction with PR recruits it to hormone response elements in 
the MMTV promoter. NURF remodeling activity at the MMTV promoter creates a 
nucleosome free region, allowing the transcription factor NF1 to bind and stimulate 
transcription (360). SNF2L also interacts with PR to regulate StAR expression in 
granulosa cells, indicating a role for NURF in oocyte development (361).   
1.7.4.3.1 The NURF Complex in Cancer Biology 
Two reports document that SNF2L expression is important for the growth of 
human cancer cell lines. In these studies, SNF2L was found to be expressed in a wide 
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variety of normal tissues, tumors, and cancer cell lines. KD of SNF2L in several cancer 
cell lines resulted in reduced cell proliferation, arrest in G2/M, increased DNA damage 
and activation of DNA damage repair pathways (phosphorylation of CHK1/2, ATM, and 
p53), and apoptosis (362). Follow-up studies identified SNF2LT as a splice variant of 
SNF2L that lacks its HAND–SANT–SLIDE domains. In these follow-up studies, they 
observed that KD of SNF2LT or the full-length SNF2L gene resulted in similar cancer 
cell-specific phenotypes (363). Similar KD studies have shown that SNF2L is an 
essential regulator of the Wnt signaling pathway (364). In these experiments, contrary to 
previous SNF2L studies, SNF2L depletion increased proliferation and chemotaxis. This 
study used genome-wide gene expression profiling to discover that many targets of the 
Wnt signaling pathway are upregulated with SNF2L KD. 
BPTF resides on 17q and is frequently duplicated in several cancer types, with 
the greatest frequency in neuroblastoma (365). A nonreciprocal translocation of BPTF 
on 17q was characterized in a human lung cell line following continuous culturing (366). 
This translocation resulted in increased BPTF expression and correlated with increased 
cell proliferation and KD of BPTF in these cells reduced proliferation. Consistent with 
the frequent duplication of 17q in human tumors, the BPTF gene was found to be 
amplified in various human tumors, especially neuroblastomas and lung cancers and 
many human cancer cell lines. Whether BPTF duplication provides an advantage to 
cancer cells, or is just a benign consequence of the 17q duplication, needs to be 
specifically addressed. High expression of BPTF in colon cancer and hepatocellular 
carcinoma is associated with high expression of epithelial-to-mesenchymal (EMT) 
markers and poor prognosis (367,368). Several genome-wide and exome studies have 
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identified mutations in BPTF to be associated with lung, bladder and BRCA1+ breast 
cancer (369-371). In these studies, KD of BPTF in bladder cancer cells reduced colony 
formation in vitro. In another bladder cancer study, H2A.Z overexpression and elevated 
incorporation into nucleosomes recruits BPTF, which promotes the expression of 
normally repressed genes. This contributes to the genomic instability of bladder cancer 
cells and contributes to the expression of oncogenes, like cyclin D1 (CCND1) (372). In 
pancreatic cancer, BPTF interacts with the oncogene c-MYC and helps recruit it to its 
gene targets. This interaction is necessary for c-MYC dependent proliferation and 
replication stress. The authors further showed that BPTF KO reduced pancreatic tumor 
growth in mice and prolonged survival (373). BPTF regulates many cell cycle genes in 
lung adenocarcinoma and BPTF KD suppresses proliferation (374). In melanoma, BPTF 
promotes both metastasis and proliferation and high BPTF expression correlates with 
poor prognosis in a study of melanoma patients. In this study, BPTF was found to 
promote the MAPK pathway, which regulates the cell cycle genes BCL2, BCL-XL and 
CCND2. Additionally, BPTF expression lends resistance to BRAF inhibition therapy 
(375). Other BPTF regulated genes involved in tumor cell biology include twist, N-
cadherin, E-cadherin and MHC class I and II genes (350,351,355,367). Because NURF 
regulates genes involved in multiple hallmarks of cancer, including tumor cell growth, 
invasion and immunogenicity, we sought to understand the role of NURF in breast 
cancer and melanoma using mouse models. 
Section 1.8: Mouse Tumor Models 
Three mouse mammary carcinoma cell lines are used in this study: 4T1, 66cl4 
and 67NR. These three lines were isolated by sequential dissemination from a single 
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spontaneous tumor harvested from a BALB/cfC3H mouse (376). The 4T1 subpopulation 
is highly metastatic through the blood to the liver, lung, bone, lymph nodes and brain, 
the 66cl4 subpopulation is metastatic through the draining lymph node to the liver and 
lung and the 67NR subpopulation is nonmetastatic (376,377). All three lines are triple 
negative for hormone receptor expression and the 4T1 model is frequently used in 
breast cancer research as it is a good model for advanced stage human breast cancer 
(378,379). The fourth tumor line used in this study is the mouse melanoma B16F10 cell 
line. It is a highly metastatic subpopulation of B16, which was isolated from a 
spontaneously arising tumor in a C57BL/6 mouse (380). B16F10 metastasizes through 
the draining lymph node to the lungs (381).  
The immunogenicities of 4T1 and B16 have been well studied in vivo. The 4T1 
tumor model is highly immunogenic, meaning it expresses high levels of MHC 
molecules and has high levels of infiltration by both antitumor and immunosuppressive 
immune cells, including M1 and M2 macrophages, DCs, Tregs, MDSCs, T cells and B 
cells. The B16 model, on the other hand, is poorly immunogenic and contains low 
numbers of both antitumor and immunoregulatory immune cells in the tumor 
microenvironment. Interestingly, qRT-PCR of B16 tumors revealed high levels of CTLA-
4 and low expression of MHC I (382). Consequently, these two models have adapted 
two different mechanisms to avoid destruction by the immune system: 4T1 tumor cells 
escape destruction from infiltrating effector cells by recruiting immunosuppressive cells 
and B16 tumor cells avoid detection from immune cells by loss of antigenicity. Because 
the 66cl4 and 67NR are much less well studied, their immunogenicities are unknown. It 
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is known, however, that 67NR cells express MHC I, and not II, molecules and lack 
expression of the costimulatory molecules B7-1 and B7-2 (383). 
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Chapter 2 
Materials and Methods 
 
2.1: Mice 
BALB/cJ, C57BL/6J, NOD/SCID, Ifrg2r -/- (NSG), NOD.CB17-Prkdcscid/J, (NOD 
scid) B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J (Pmel) (Jackson Laboratories) and 
C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT1) (Gift from Dr. Shawn Wang, VCU) female mice 
6-8 weeks of age were housed under aseptic conditions. These studies have been 
approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia 
Commonwealth University. 
 
2.2: Cell Culture 
4T1, 67NR, 66cl4 (Fred Miller, Wayne State University), B16F10 and HEK 293T 
(ATCC) cells were cultured in complete media (CM) (Dulbeco’s Modified Eagle Medium 
[DMEM] [Thermo-Fisher], 10% fetal bovine serum [FBS] [Hyclone], 1% nonessential 
amino acids [NEAA] [Thermo-Fisher], 2 mM glutamine [Thermo-Fisher] and 1% 
Pen/Strep [Thermo-Fisher]). The 67NR and 66cl4 lines were isolated from the same 
tumor as 4T1. 66cl4 is metastatic through the lymph and 67NR is nonmetastatic (376). 
T cells were cultured in CM with 10 mM HEPES (Thermo-Fisher), 5x10-5 M ß-
mercaptoethanol (Sigma) and 50 U/ml recombinant mouse IL-2 (R&D Systems). 
Hybridoma lines were cultured in Roswell Park Memorial Institute medium (RPMI-1640) 
(Life Sciences), 10% FBS, 1% NEAA, 2 mM glutamine and 1% Pen/Strep. Cell lines 
were authenticated by ATCC prior to shipment by short tandem repeat profiling. 
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Mycoplasma contamination was tested and confirmed to be negative every 2 years 
using Universal Mycoplasma Detection Kit (ATCC). 
Short-hairpin RNAs (shRNA) were introduced into 4T1, B16F10, 67NR and 66cl4 
cells using Moloney murine leukemia virus (MMLV) using the pSIREN-RetroQ 
(Clonetech) system. pSIREN plasmids Ctrl-sh1, Ctrl-sh2, Bptf-sh1 (4T1), Bptf-sh2 
(4T1), Bptf-sh1 (B16F10, 67NR, 66cl4), Bptf-sh2 (B16F10) and Bptf-sh2 (67NR, 66cl4) 
are available at Addgene as stock numbers 73665, 73666, 73669, 73668, 73667, 73669 
and 83045, respectively. Transduced cells were selected with 0.5 µg/ml puromycin (Life 
Technologies) after 48 hours (hr) and maintained in CM containing puromycin 
thereafter. 
 
2.3: Population Doubling Time  
1x104 4T1, B16F10, 67NR or 66cl4 cells were plated in triplicates and counted 
using a hemocytometer every 24 hours for 4 consecutive days. 5 counts were taken per 
sample. Population doubling times were calculated using http://www.doubling-time.com. 
These measurements were repeated for 3 independent cell line pools. 
 
2.4: Tumor Studies 
1x104 4T1 cells, 1x105 67NR cells or 1x104 66cl4 cells were injected 
subcutaneously (S.C.) into the fourth mammary fat pad of BALB/c or NSG mice. 5x104 
B16F10 cells were injected S.C. into the flank of C57BL/6 mice. Viable tumor cells were 
assessed with 0.2% trypan blue using a Cellometer Auto T4 cell counter (Nexcelom). 
Cells were resuspended in DMEM and 50 µl single cell suspension was injected into 
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mice. Tumors were analyzed at 21 days (4T1, 67NR), 28 days (66cl4) or 18 days 
(C57BL/6). For gemcitabine treated mice, 1x105 4T1 or 5x105 B16F10 cells were 
injected into BALB/c, NSG or C57BL/6 mice and 1.2 mg/mouse gemcitabine (Hospira) 
was injected intraperitoneously (I.P.) on day 5 and every 7 days following until tumors 
were analyzed on day 37 (4T1) or day 18 (B16F10).  
2.5: Monoclonal Antibody Depletions 
To generate ascites fluid, NOD scid mice were injected I.P. with 200 µl pristane 
(Sigma) 14 days prior to I.P. injection of 5x106 GK1.5 (anti-CD8), 2.43 (anti-CD4) (Gift 
from Dr. Mosoud Manjili, VCU) or SH-34 (anti-asialo GM1) (ATCC) hybridoma cells in 
100 µl. Once abdominal distension was noticeable, animals were tapped by inserting a 
sterile 22 gauge needle into the abdominal cavity and withdrawing fluid with a 5 ml 
syringe. Animals were tapped three times each. Ascites fluid for each antibody was 
pooled and centrifuged at 10,000 x rcf for 30 min at 4°C. The supernatant was 
transferred to a new tube and saturated ammonium sulfate was added drop wise to 
reach a final concentration of 25%. The sample was incubated overnight at 4°C, 
centrifuged, and the supernatant was transferred to a new tube. Saturated ammonium 
sulfate was added drop wise to reach a final concentration of 50% and the sample was 
incubated overnight at 4°C. The sample was then centrifuged and the pellet was 
resuspended in 1/5 the starting volume of phosphate-buffered saline (PBS). The sample 
was then dialyzed against a 3,500 KDa tube with 5 changes of PBS. Protein 
concentration was then measured using the DC Protein Assay and samples were run 
on a 10% SDS-PAGE gel to verify antibody presence in the sample. 
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225 µg/mouse in 100 µl mAb was injected I.P. into BALB/c or C57BL/6 mice on 
day -2 and day -1 and mice were inoculated with 4T1, B16F10, 67NR or 66cl4 tumor 
cells on day 0. mAb was injected once every 5 days following tumor inoculation and 4T1 
tumor bearing mice were treated with gemcitabine as described. Efficient depletion of 
CD8+, CD4+ and NK cells was confirmed by flow cytometry analysis of splenocytes. 
2.6: Metastasis Assay 
Lungs from 4T1 tumor bearing BALB/c mice were minced and digested in 5 ml of 1 
mg/ml collagenase type IV (Sigma) in hank’s balanced salt solution (HBSS) for 75 min 
at 4°C. The digested lungs were filtered through a mesh 40 µm filter and centrifuged at 
400 x rcf for 8 min. The supernatant was removed and cells were washed with 10 ml 
HBSS, followed by a 10 ml CM wash. Cells were then resuspended in 10 ml CM 
containing puromycin and 60 µm 6-thioguanine and plated on a 10 cm dish. After 14 
days, colonies were washed with 5 ml PBS and stained with 5 ml 2% methylene blue in 
50% methanol for 10 min. Plates were washed with water and colonies were counted.  
 
2.7: Protein Extraction 
For total cell lysates, cells were washed in PBS and lysed with trizol (Sigma) for 10 min 
at RT. For tumor extracts, tumors were minced and homogenized using a Polytron 
homogenizer (IKA) and lysed in 1 ml trizol per 100 mg tissue. 200 µl chloroform per ml 
trizol was added and samples were vortexed and incubated for 15 min at RT. Extracts 
were centrifuged at 12,000 x rcf for 15 min at 4°C and the organic phase was moved to 
a new tube. 1 ml isopropanol per ml trizol was added to the organic phase and samples 
were mixed and incubated for 10 min at RT. Extracts were centrifuged at 12,000 x rcf 
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for 10 min at 4°C and the supernatant was removed. 1.5 ml 0.3 M guanidine in 95% 
ethanol per ml trizol was added to the samples and incubated overnight at 4°C. 
Samples were centrifuged at 12,000 x rcf for 10 min at 4°C and the supernatant was 
removed. 1.5 ml 100% ethanol per ml trizol was added, samples incubated for 8 hrs at 
4°C and centrifuged at 12,000 x rcf for 10 min at 4°C. The supernatant was removed 
and extracts were dissolved overnight at 65°C in 200 µl 8M urea in 1% SDS per ml 
trizol.  
For cell surface extracts, cells were washed with PBS and removed from the dish 
using a cell scraper. Cells were then lysed in lysis buffer (20 mM phosphate buffer, pH 
7.4, 350 mM NaCl, 10 mM KCl, 1 mM EDTA, 1% Triton X-100, 20% glycerol) 
supplemented with EDTA-free protease inhibitor cocktail (Roche) for 3 hrs at 4°C. 
Samples were centrifuged at 10,000 x rcf for 30 min at 4°C to remove large aggregates 
and the supernatant was transferred to a new tube. 
Protein was quantified using the DC Protein Assay (Bio-Rad) according to the 
manufacturer’s instructions with a Ultrospec III spectrophotometer (Pharmacia LKP). 
 
2.8: Western Blot 
40 µg protein was loaded into SDS-PAGE gels and elecrophoresed for 1 hr at 
200 V and 300 mA. Protein was transferred to a PVDF membrane (Bio-Rad) for 1-1.5 
hrs at 200 V and 200 mA in transfer buffer (10 mM CAPS-NaOH pH 10.5). Membranes 
were blocked with 5% nonfat dry milk in PBST (PBS 0.1% Tween-20) for 1 hr at RT. 
Membranes were incubated with primary antibodies overnight at 4°C: 1:5000 anti-BPTF, 
1:10,000 anti-HS (Millipore), 1:1000 anti-OVALBUMIN, 1:1000 anti-PMEL17, 1:10,000 
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anti-HPSE (Santa Cruz Biotechnology), 1:10,000 anti-CYCLOPHILIN B (Abcam), anti-
PSMB9, anti-TAP2 (Thermo Scientific), anti-PSMB8 and anti-TAP1 (Cell Signaling). 
Membranes were washed 3 times with PBST for 5 min at RT and incubated with 
secondary antibody for 1 hr at RT: 1:10,000 horseradish peroxidase (HRP)-conjugated 
anti-rabbit or anti-mouse secondary antibody (Cell Signaling). Membranes were then 
washed 3 times with PBST for 5 min each and exposed with electrochemiluminescence. 
Loading was determined by cyclophilin B. 
 
2.9: RNA Extraction 
Cultured cells and tumors were prepared and treated with trizol as described in 
the Protein Extraction section. 500 µl isopropanol per ml trizol was added to the 
aqueous phase containing the RNA, samples were mixed, incubated for 10 min at RT 
and centrifuged at 12,000 x rcf for 10 min at 4°C. The RNA pellet was washed with 1 ml 
70% ethanol per ml trizol, dried for 10 min at RT and resuspended in 100 µl molecular 
grade water. RNA quality was verified by nanodrop and degradation was assessed by a 
0.8% agarose gel. 
 
2.10: qRT-PCR  
5 µg RNA was reverse transcribed to cDNA using Superscript II First-strand kit 
(Invitrogen) according to the manufacturer’s instructions. qPCR was performed using 
SYBR green PCR master mix (Biorad) with a 7900 HT fast real-time qPCR system 
(Applied Biosystems). 5 µl cDNA, 5 µl 280 nM forward and reverse primer mix and 10 µl 
2X SYBR green ROX mix were mixed together for each reaction. qRT-PCR conditions: 
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95°C for 15 min, 50 cycles of 95°C for 10 sec, 60°C for 30 sec and 72°C for 30 sec, 
followed by a dissociation curve cycle. The ddCt method was performed using 
normalization to Gapdh. Primer pairs are found in a Table 2.1. 
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Table 2.1: Primers used for qRT-PCR 
qRT-PCR Primers  
Mouse Primers  
Gapdh Forward TGGCAAAGTGGAGATTGTTGCC 
Gapdh Reverse AAGATGGTGATGGGCTTCCCG 
Psmb9 Forward CTCTGCTGAGATGCTGCGGGC 
Psmb9 Reverse CCACTGCTGTTCCCGCTGACAC 
Psmb8 Forward TTGGCCAAGGAGTGCAGGTTGTAT 
Psmb8 Reverse GTCCCGAGAGCCGAGTCCCAT 
Tap1 Forward TCGGGAATGCTGCTGAAGCTTC 
Tap1 Reverse GGGTGCCAACGAGCCACTGA 
Tap2 Forward CGCCTTTGCAAGCGCCATCTTT 
Tap2 Reverse TCGAGTTCAGCTCCCCGTGCTT 
B2m Forward GTCGCTTCAGTCGTCAGCAT 
B2m Reverse GATCACAGTGCTCGATCCCAG 
H2K1 Forward CAGAACTCAGAAGTCGCGAATCGCC 
H2K1 Reverse ACGAACTCCGTGTCGTCCACG 
H2D1 Forward GAGCCTCCTCCGTCCACTGACTC 
H2D1 Reverse CCAGGCAGCTGTCTTCACGCTTTA 
Oas1a Forward CATTTCAGCTAGGCTGGGGAGACCC 
Oas1a Reverse GAGCCACCCTTCACCACCTTGGA 
Oas2 Forward CCTGGCTGTACTCTCCCAGCCT 
Oas2 Reverse TGGCAGTGGATCCTCCCTTGACG 
Hpse Forward (67NR) GAGCGGAGCAAACTCCGAGTGTATC 
Hpse Reverse (67NR) GATCCAGAATTTGACCGTTCAGTT 
Hpse Forward (66cl4) GGAAATCTCAAGTCAACCATGATAT 
Hpse Reverse (66cl4) ATCTCCACTGAGCTTCTTGAGTAG 
Human Primers  
Gapdh Forward CTCTGCTCCTCCTGTTCGAC 
Gapdh Reverse GCGCCCAATACGACCAAATC 
Hpse Forward GGCAAGTATTCTTTGGAGCA 
Hpse Reverse TGGATTGTCAGTGTTTGTGC 
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2.11: Flow Cytometry  
Cultured tumor cells were washed with PBS and collected with Cellstripper 
(Corning). Cells were washed and resuspended in FACS buffer (2% FBS in HBSS) and 
stained with 0.5 µl H2K, H2D, H2A, Qa1, OVA antibodies or Annexin V for 20 min at 
4°C. Cells were then washed twice with FACS buffer and suspended in 500 µl FACS 
buffer with 1 µl 7AAD viability dye (Sigma).  
To stain infiltrating lymphocytes, tumors were minced and digested in HBSS with 
0.04% DNase I (Sigma) and 0.1% collagenase type IV for 90 min at 37°C. Tumor 
digests were filtered through a 40 µM nylon filter and centrifuged at 500 x rcf for 5 min at 
RT. Percoll was thawed to RT and 9 volumes percoll were mixed with 1 volume 10x 
PBS to obtain the working concentration. Cells were resuspended in 40% percoll 
(Sigma), layered on top of 70% percoll and centrifuged at 3000 x rcf for 30 min at RT 
with 0 acceleration and 0 brake. Lymphocytes at the interphase were removed, diluted 
in PBS, and centrifuged at 500 x rcf for 5 min at RT. Purified lymphocytes were 
subsequently stained with 0.5 µl CD8, CD69, TCRb, CD44, or BTLA antibodies and 
7AAD viability dye.  
For NK receptor binding, 1x105 67NR or 66cl4 cells were washed with PBS, 
collected with trypsin and incubated with 1 µg Ncr1-Ig (gift from Ofer Mandelboim from 
The Hebrew University of Jerusalem) for 1 hr at 4°C. Cells were washed twice with 
FACS buffer and stained with 0.5 µl PE- anti-human-IgG Fc (Biolegend) for 20 min at 
4°C. For heparinase treatment, 67NR or 66cl4 cells were treated with 10 U/ml bacterial 
heparinase I/III (Sigma) in DMEM 1% BSA for 1 hr at 37°C. 1x105 cells were then 
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collected with trypsin and incubated with 1 µg Ncr1-Ig, washed, stained with PE- anti-
human-IgG Fc and analyzed by flow cytometry.  
All flow cytometry data collection was performed using a FACSCalibur flow 
cytometer (Becton Dickinson) and analyzed using Cyflogic software. All antibodies were 
purchased from BD Pharmingen.  
 
2.12: T Cell Cytotoxicity Assay  
Spleens from 4T1 or B16F10 tumor bearing mice were collected and cut 
lengthwise. Splenocytes were extracted by gentle massaging and suspended in MACS 
buffer (0.5% BSA, 2 mM EDTA in PBS). Splenocytes were filtered through a mesh 0.40 
µm filter and counted with a hemocytometer. MDSCs were removed by positive 
selection using the Myeloid-Derived Suppressor Cell Isolation Kit, mouse according to 
the manufacturer’s instructions (Miltenyl). CD8a+ cells were then purified by negative 
selection using the CD8a+ T Cell Isolation Kit mouse (Miltenyl) according to the 
manufacturer’s instructions. For CTL hyperactivation assays, purified CD8+ T cells were 
directly treated with 0.8 µM PMA, 0.35 µM Ionomycin and placed on mitomycin C-
treated tumor cells. For polyclonal CTL assays, the purified CD8+ T cells were 
cocultured with 5x104 mitomycin C-treated 4T1 or B16F10 tumor cells in one well of a 
24 well plate for 1-3 weeks of in vitro expansion in T cell media with 500 U/ml IL-2. The 
CD8+ T cells were then harvested and purified by percoll gradient a mini percoll 
gradient: 2 ml 40% percoll layered on top of 1 ml 70% percoll. Lymphocytes recovered 
from the interphase were cocultured with 5x103 mitomycin C-treated tumor cells for 
assay.  
85 
 
For total splenocyte and OVA analysis, splenocytes from tumor bearing mice or 
naïve OT1 mice were collected and red blood cells were removed by 5 min incubation 
at RT with red blood cell lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA). 
Splenocytes were then restimulated in vitro for 1-3 weeks before coculture with targets 
for assay. For ONX-0914 treatment, ONX-0914 was added to mitomcyin C treated 
targets for 24 hours. Cells were then placed in fresh media and incubated with 
splenocytes at a 50:1 effector:target ratio.  
For all assays, CD8+ T cells/splenocytes were cocultured with 5x103 targets in V-
bottom 96 well plates for 48 hours in LDH media (DMEM, 5% heat inactivated FBS 
(Serum Source), 1% NEAA, 2 mM glutamine and 1% Pen/Strep) with 500 U/ml IL-2. 
Cell death was measured using the CytoTox 96® Non-Radioactive Cytotoxicity Assay 
according to the manufacturer’s instructions (Promega). Percent cytotoxicity was 
calculated using (Experimental – Effector Spontaneous – Target Spontaneous)/(Target 
Maximum – Target Spontaneous) x 100. 
 
2.13: NK Cell Cytotoxicity Assay 
Mouse NK cells were purified from the spleen of naïve BALB/c mice by negative 
selection using the NK Cell Isolation Kit II mouse (Miltenyl) and placed on mitomycin C-
treated targets for assay. For antibody blocking experiments, NK cells were pre-
incubated for 1 hour with 10 µg/ml blocking antibody in 100 µl to mNcr1 (NK1.15 from 
Stipan Jonjic, University of Rijeka). For hyperactivation, purified mouse NK cells were 
treated with 0.8 µM PMA, 0.35 µM Ionomycin in cocultures. For media preconditioning, 
mitomycin C treated targets were incubated in 6 well plates for 24 hours. The media 
86 
 
was then removed and incubated with freshly purified NK cells for 24 hours. NK cells 
were then plated on mitomycin C treated targets for assay. For heparin competition 
experiments, heparin (Sigma) was added to the coculture experiment to 100 µg/ml final. 
For heparinase treatment, mitomycin C treated 66cl4 cells were pretreated with 1 U/ml 
bacterial heparinase I/III (Sigma) for one hour at 37°C, washed, and cocultured with NK 
cells for assay.  
For all NK cytotoxicity assays, mouse NK cells were cocultured with 5x103 
targets in LDH media with 50 U/ml IL-2 for 24 hours and cell death was measured using 
the CytoTox 96® Non-Radioactive Cytotoxicity Assay.  
 
2.14: Enzyme-Linked ImmunoSpot (ELISPOT) 
Coat MultiScreen-IP plates (Millipore) were coated with 10 μg/ml rat anti-mouse 
IFN-γ (clone R4-6A2)(BD Pharmingen) at overnight 4°C. Plates were washed twice and 
blocked with CM containing 10% FBS for 2 hrs at 37°C. Splenocytes from naïve mice 
and B16F10 tumor infiltrating lymphocytes were obtained as described above and 2x106 
lymphocytes were cocultured with 1x106 splenocytes. Cocultures were stimulated with 1 
µg/ml Gp10025–33 (KVPRNQDWL), TRP2180-188 (SVYDFFVWL) or p15E604-611 
(KSPWFTTL) and 50 U/ml IL-2 for 96 hours at 37°C. Plates were then washed once 
with distilled water, 6 times with PBS 0.05% Tween-20, and incubated with 5 μg/ml 
biotinylated IFN-γ antibody (clone R4-6A2)(BD Pharmingen) in PBS 1% BSA for 2 hrs at 
37°C. Plates were then washed 6 times with PBS 0.05% Tween-20 and incubated with 
0.2 unit/ml avidin-alkaline phosphatase D (Vector) for 2 hrs at RT. 5-bromo-4-chloro-3-
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indolyl phosphate/nitroblue tetrazolium (Vector) was added and spot development was 
monitored for 20 min at RT. 
 
2.15: Limited Dilution 
CD8+ T cell clones were purified and expanded as described above. After one 
week of in vitro expansion, clones were diluted in media to ~ 1 cell/ 100 µl and 100 µl 
was plated to each well of a V-bottom 96 well plate on 1x104 mitomycin C treated 4T1 
targets. Media was changed approximately three times a week and clones were placed 
on new targets approximately once every 2-3 weeks. After ~3 months, wells were 
screened for live T cells by enzyme-linked immunosorbent assay (ELISA) using the 
Ready Set Go Interferon Gamma ELISA kit (eBioscience) according to the 
manufacturer's instructions. After ~6 months, clones identified by ELISA were divided 
into 2 wells each, and after ~1 year, clones were moved to a single well of a 24 well 
plate on 5x104 targets. Clones were assayed for activity against control and BPTF KD 
targets as described above, with 50 U/ml IL2. 
 
2.16: Chromatin Immunoprecipitation (ChIP)  
Cultured cells of equal confluency were fixed in 10 ml 1% paraformaldehyde in 
PBS for 15 min at RT. Cells were washed 3 times with PBS and removed from the plate 
using a cell scraper. Cells were transferred to a slick 1.5 ml Eppendorf tube and 
centrifuged at max speed for 1 min at RT. The supernatant was removed and cells were 
resuspended in 1 ml lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.0) 
supplemented with protease cocktail inhibitor. Chromatin was sheared to an average 
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size of 300 bp by 3 rounds of 15 min alternating 30 sec on, 30 sec off Bioruptor 
sonication (Diagenode). Samples were then centrifuged at max speed for 15 min at RT. 
The supernatant was divided and transferred to a slick tube with either 0.5 µg anti-BPTF 
(Millipore) or control rabbit IgG (Cell Signaling) bound to Protein G Dyna beads (Life 
Technologies) diluted in 1.6 ml dilution buffer (1.1% Triton X-100, 1.2 mM EDTA, 16.7 
mM Tris HCL pH 8.0, 167 mM NaCl) supplemented with protease cocktail inhibitor. 40 
µl of the supernatant was removed for 10% input. Samples were bound to antibodies 
overnight at 4°C. Samples were subsequently washed with 500 µl low salt buffer (1% 
Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 150 mM NaCl), high salt buffer (1% 
Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 500 mM NaCl), LiCl buffer (0.25 M LiCl, 
1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris HCl pH 8.0) and 
two washes with TE buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA) for 5 min on ice each. 
Antibody was then eluted twice with elution buffer (250 µl 0.1 M NaHCO3 in 1% SDS) 
for 30 min at RT. 460 µl elution buffer was added to inputs and all samples and inputs 
were incubated with 20 µl 5 M NaCl at 65°C overnight. Samples/inputs were 
subsequently incubated with 10 µl 0.5 M EDTA, 20 µl 1 M Tris and 2 µl 10 mg/ml 
proteinase K at 45°C for 1 hour to reverse the crosslinks. 2 µl glycogen and 500 µl basic 
phenol/CHCl3 were added to samples/inputs, which were then vortexed for 5 min. 
Samples/inputs were centrifuged at max speed for 15 min at RT and the aqueous phase 
was transferred to new slick tubes. DNA was precipitated with 2.5x volume of 100% 
ethanol overnight at -20°C and samples/inputs were centrifuged at 15000 x rpm for 30 
min at 4°C. The supernatant was removed and pellets were washed with 500 µl 70% 
ethanol, dried by Savant SpeedVac sc100 and resuspended in 50 µl molecular grade 
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water. qRT-PCR was performed as described above. Primer pairs are found in Table 
2.2. 
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Table 2.2: Primers used for ChIP 
 
 
        
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
ChIP qRT-PCR Primers  
Site 1 Forward AGAGCTGTGGAGTTGAAGCT 
Site 1 Reverse CCACCTTACCTCCCCACAAT 
Site 2 Forward CAGGGGAGGTGGAGTCACTA 
Site 2 Reverse TGGTTCTTCCTTACAGAACAGCA 
Site 3 Forward (4T1) CAGGCTAGGACCAGACTCTG 
Site 3 Reverse (4T1) GAGAAGATTCCCGGGAGCAT 
Site 3 Forward (B16F10) GATCACTCCACCCGCTGAC 
Site 3 Reverse (B16F10) TTTGCTCTGGGCGCCAAAT 
Site 4 Forward AGCTCTAGGGGTTCTGATGC 
Site 4 Reverse CCATGTCCTCCTCCTCATCG 
Site 5 Forward ACGCCTAGGTGGATCTGCT 
Site 5 Reverse TTGGGGACGAGTTTTCCTGC 
Site 6 Forward GGCAGTGAAGTGAAAGCGAA 
Site 6 Reverse ATGATGACGCCAAGGGTTTG 
Site 7 Forward CCCAACCCTAACTCCACCAT 
Site 7 Reverse GTGTGGGGTAGGGTTCTGTT 
Site 8 Forward CTCACACCCATCCACCTCTT 
Site 8 Reverse TGGAAGAGCAGCCTTAACCA 
Site 9 Forward CCCAAACCAAAACCCTCCAG 
Site 9 Reverse AACTGGCGCGGAAATTACAG 
Enhancer Forward  GAGGAACCGGCTACTCTCCT 
Enhancer Reverse GTGTGGGCCAAGATGGAAGT 
Promoter Forward GGTGGCCAGAATCCAAGATCC 
Promoter Reverse AAAAACAGGGTCCCCACCAC 
Intragenic Forward ACCTCCACACTGGGTTTGAC 
Intragenic Reverse TGTGTCTGGTCCTCGTTTGG 
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2.17: Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE) 
Cultured cells of equal confluency were fixed with 10 ml 1% paraformaldehyde in 
PBS for 15 min at RT. Cells were washed 3 times with PBS and removed from the plate 
using a cell scraper. Cells were transferred to a slick 1.5 ml Eppendorf tube and 
centrifuged at max speed for 1 min at RT. The supernatant was removed and cell 
pellets were resuspended in 500 µl FAIRE lysis buffer (10 mM Tris HCl pH 8.0, 2% 
Triton X-100, 1% SDS, 100 mM NaCl, 1 mM EDTA) supplemented with protease 
inhibitor cocktail. Chromatin was sheared to an average size of 300 bp by 3 rounds of 
15 min alternating 30 sec on, 30 sec off Bioruptor sonication and samples were 
centrifuged at max speed for 15 min at RT. 450 µl (sample) and 50 µl (input) were 
transferred to new tubes. 1 µl DNase-free RNase A was added to the input and 
incubated for 30 min at 37°C. 1 µl proteinase K was then added and inputs were 
incubated for 1 hr at 55°C and overnight at 65°C to reverse the crosslinks. 100 µl 10 
mM Tris HCl pH 7.4 was then added to inputs. 1 volume phenol/chloroform/isoamyl 
alcohol solution was added to both inputs and samples, vortexed and centrifuged at 
12,000 x rcf for 5 min at RT. The aqueous phase was transferred to a new tube and 150 
µl 10 mM Tris-HCl pH 7.4 was added to the interphase/organic phase. The 
interphase/organic phase samples were then vortexed and centrifuged and the aqueous 
layer was pooled with the previous aqueous extraction layer. One more round of 
phenol/chloroform/isoamyl alcohol extraction was performed and the aqueous phase 
was transferred to a new tube. 200 µl chloroform/isoamyl alcohol was added to the 
aqueous phase, vortexed, and centrifuged. The aqueous phase was transferred to a 
new tube and incubated with 1/10 volume 3 M sodium acetate pH 5.2, 2 volumes 95% 
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ethanol and 1 µl linear acrylamide at -80°C overnight. Samples/inputs were precipitated 
by centrifugation at 12,000 x rcf for 15 min at 4°C, washed with 500 µl 70% ethanol and 
dried by SpeedVac. Pellets were resuspended in 20 µl (inputs) or 50 µl (samples) 10 
mM Tris HCl pH 7.4. Samples/inputs were then purified using Zymo-I spin columns 
(Zymo Research): DNA binding buffer was mixed with the DNA at a 2:1 ratio and 
passed through the column via high speed centrifugation for 1 min. The column was 
washed twice with 200 µl wash buffer and DNA was eluted with TE buffer. 
qRT-PCR was performed as described and FAIRE results were normalized to a 
control locus which does not have BPTF dependent FAIRE when normalized to equal 
DNA mass. Primers are found in Table 2.3. 
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    Table 2.3: Primers used for FAIRE 
FAIRE qRT-PCR Primers  
Site 1 Forward CGCAGTCTAGAGTGAAAGCGA 
Site 1 Reverse CATGCGAAGCTGGTGAGAAG 
Site 2 Forward AGGCAACTTGCAGACTGAGG 
Site 2 Reverse AGATTTGCCCTGCTCAGGTT 
Site 3 Forward TTCCTCTAAACGCCAGCACT 
Site 3 Reverse GAAGGAAGAAGGGCGGGTC 
Control Site Forward ATACAACCAAACAGACACACAACC 
Control Site Reverse CTACTGGCTGCCATGGCTTA 
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2.18: Microarray  
RNA extraction, microarray analysis and statistical analysis were performed as 
described (384,385). Tumor tissues were subjected to gross histological analysis using 
hematoxylin and eosin staining to determine percentages of tumor, necrotic and stromal 
cells before tissues were isolated for RNA extraction. If present, necrotic tissue was 
selected out by macrodissection. Total RNA was then extracted from frozen tumor 
tissues with TRI reagent and the MagMAX-96 Total RNA Isolation Kit in a MagMAX 
Express Magnetic Particle Processor (Life Technologies). RNA quality was assessed 
with an Agilent 2100 Bioanalyzer and NanoDrop 8000 spectrophotometer. 5 μg of total 
RNA was reverse transcribed and the GeneChip 3’ IVT Express kit (Affymetrix) was 
used to generate biotinylated cRNA by in vitro transcription. 10 μl of fragmented cRNA 
was applied to the GeneChip®Mouse Genome 430A 2.0 Array (hybridization conditions: 
60 x rpm for 16 hrs at 45°C)(Affymetrix). Microarrays were then washed and stained 
with streptavidin phycoerythrin (Molecular Probes) using an Affymetrix Fluidics work 
station. Microarrays were scanned as previously described using the Affymetrix 
GeneChip Scanner 3000 and data was saved as .dat and .cel files. Array quality was 
accepted if the 3’/5’ ratio of the housekeeping gene GAPDH is less than three and the 
present gene percentage is more than 40%.  
Microarray statistical analysis was performed as previously described (384,385). 
Log-scale robust multiarray analysis (RMA) was used for noise correction, normalization 
and estimation for probe expression. Relative differences between control and KD 
samples were analyzed using two-sample-t-test for each pairwise comparison with α-
level equal to 0.01 to determine differentially expressed probes at the univariate level. 
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Each p-value was corrected for multiple testing using FDR false discovery rate < 15%. 
Data are available at GEO accession GSE71864 and GSE785756. 
 
2.19: Statistical Analysis 
All variation shown represent standard deviation from the mean and all tests of 
significance were tested with a student’s unpaired two-tailed t-test. 
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Chapter 3 
BPTF Depletion Enhances T Cell Mediated Antitumor Immunity 
 
3.1 BPTF Depletion Increases T Cell Antitumor Immunity to 4T1 Tumors 
Consistent with previous work showing that the subunits of the NURF complex 
are frequently overexpressed in cancer cells (346), we found each of the NURF 
subunits is expressed in a variety of mouse tumor cell lines (Fig. 3.1A). To discover 
functions of NURF in cancer cell biology, we repressed BPTF expression in mouse 4T1 
cells by retroviral introduced shRNA KD (Fig. 3.1B). BPTF KD was used to deplete 
NURF because it is unique and essential to the complex (286,352). Surprisingly, BPTF 
KD cells showed no significant differences in doubling time, considering previous 
studies have shown decreases in proliferation with BPTF KD (Fig. 3.1C) (366,374,375). 
Additionally, we observed no differences in in vitro cellular morphology or levels of 
apoptosis (Fig. 3.1D and E).  
To uncover functions for BPTF in tumor biology, we introduced BPTF KD 4T1 
cells into the 4th mammary fat pad of syngeneic BALB/c mice. As part of our studies, 
we inoculated the cells into both untreated and gemcitabine treated mice. Gemcitabine 
is a routinely used chemotherapeutic for treating breast cancer which inhibits DNA 
replication and induces apoptosis in tumors (386). We observed significantly reduced 
weights for BPTF KD tumors only in gemcitabine treated mice (Fig. 3.2A). We chose 
weight and not volume to monitor tumor growth because BPTF KD tumors are  
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morphologically flat compared to controls, confounding a volume based measurement 
(Fig. 3.2B and C).  
In addition to inducing cancer cell apoptosis, gemcitabine also inhibits the 
proliferation of several cells of the immune system, most prominently MDSCs (57,386-
389). MDSCs are dramatically amplified in mice bearing 4T1 tumors, which suppresses 
the antitumor immune response (389). To determine if the effect of gemcitabine on 
BPTF KD tumors is a result of enhanced antitumor immunity, we repeated our tumor 
studies in immune compromised NOD/SCID, Ifrg2r -/- (NSG) mice (390). In NSG mice, 
we observed similar growth of control and BPTF KD tumors with gemcitabine treatment 
(Fig. 3.2D), demonstrating that the reduced tumor growth in BALB/c mice is not due to 
gemcitabine alone, but rather in combination with antitumor immunity. 
To determine if BPTF KD cells are eliminated from tumors grown in immune 
competent mice, we measured BPTF levels in the primary tumors. We show that BPTF 
expression increases in tumors from BALB/c (Fig. 3.2E) but not NSG mice (Fig. 3.2F), 
suggesting that a functional immune system either directly or indirectly selects for cells 
which re-express BPTF.  
To understand the immune response to gemcitabine treated BPTF KD 4T1 
tumors, we selectively depleted CD8+ T cells, CD4+ T cells or NK cells by ADCC. We 
observed a rescue of BPTF KD tumor growth when CD8+ or CD4+ cells were depleted 
(Fig. 3.2G), demonstrating that the antitumor response to BPTF KD 4T1 tumors requires 
T cells. 
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3.2 MDSC Amplification and Tumor Metastasis are BPTF-Independent 
4T1 tumors dramatically amplify MDSCs, resulting in splenomegaly with spleen 
size proportional to the degree of MDSC amplification (389). As previously reported, we  
observed a significant increase in spleen weight with introduction of 4T1 tumors into 
BALB/c mice (Fig. 3.3A). The observed increase in spleen weight was proportional to 
tumor weight and was not affected by BPTF KD, demonstrating that splenomegaly is 
BPTF-independent (Fig. 3.3B). 
The 4T1 model is also widely used to study breast cancer cell metastasis (376). 
To determine if BPTF regulates metastasis, we analyzed metastases to the lung of both 
untreated and gemcitabine treated BALB/c mice using a colony formation assay (376). 
We show that tumor size, but not BPTF KD, was significantly correlated with the number 
of colonies, suggesting that metastasis of 4T1 is BPTF-independent (Fig. 3.3C and D) 
(see discussion). 
3.3 BPTF Depletion Increases T Cell Antitumor Immunity to B16F10 Tumors 
To further verify our findings, we used the B16F10 melanoma model which is 
syngeneic to C57BL/6 (391). First, we confirmed that each NURF subunit is expressed 
in B16F10 cells (Fig. 3.4A). Additionally, BPTF KD (Fig. 3.4B) had no significant effect 
on doubling time, cellular morphology or apoptosis of B16F10 cells (Fig. 3.4C-E). 
Consistent with 4T1, B16F10 KD tumors had a flattened morphology, preventing 
caliper measurements from accurately comparing tumor growth (Fig. 3.5A and B). As 
with 4T1, we observed significant reductions in BPTF KD B16F10 tumor weights (Fig.  
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3.5C). However, unlike in the 4T1 model, gemcitabine treatment did not selectively 
reduce BPTF KD B16F10 tumor growth (Fig. 3.5D). 
To determine if CD4 and CD8 T cells are required for reduced B16F10 BPTF KD 
tumor growth, we repeated our mAb depletion experiments. Consistent with an 
enhanced T cell response, we observed a rescue of BPTF KD tumor growth with CD4+ 
and CD8+ cell  
depletion, but not NK cell depletion (Fig. 3.5E). These results in combination support a 
model of an enhanced CD8 T cell cytotoxic response to BPTF KD tumors, which 
requires CD4 T helper cell activity.  
3.4 CD8 T Cells are More Abundant and Activated in BPTF KD Tumors 
Because a T cell-mediated antitumor response was required for a reduction of 
BPTF KD tumor growth, we then measured the infiltration and activation status of 
intratumoral CD8 T cells by flow cytometry. As expected, we observed a greater number 
of CD8 T cells (CD8+, TCRb+) in the BPTF KD tumor microenvironment (Fig. 3.6A and 
B ). We next measured the abundance of activation markers CD69 and CD44 and the 
anergy marker BTLA on intratumoral CD8 T cells. We observed a greater percentage of 
CD69high CD8+ cells in both 4T1 and B16F10 BPTF KD tumors (Fig. 3.6C and D). In 
contrast, CD44 and BTLA expression differed significantly on CD8 T cells between 
control and BPTF KD B16F10, but not 4T1, tumors (Fig. 3.6E-H). This could be the 
result of differences in the tumor microenvironment between 4T1 and B16F10 (see 
Discussion). Together, these results indicate that the BPTF KD tumor microenvironment 
has a greater number of active CD8 T cells. 
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3.5 CD8 T Cells have Enhanced Cytotoxic Activity Toward BPTF KD Cells In Vitro 
To investigate if BPTF KD 4T1 and B16F10 tumor cells are more efficiently 
targeted by CD8 T cells, we performed in vitro cytotoxicity assays. Coculture of purified 
splenic CD8 T cells isolated from BPTF KD tumor bearing mice with BPTF KD targets 
results in enhanced cytolytic activity compared to similar experiments using controls 
(Fig. 3.7A).  
We next determined if BPTF KD cells are more susceptible to T cell induced cell 
death. Toward this end, we used PMA + ionomycin activated naïve CD8 T cells and 
observed similar cytolytic activity between control and BPTF KD targets (Fig. 3.7B). 
These results demonstrate that enhanced CD8 T cell killing of BPTF KD target cells was 
not due to increased sensitivity to CD8 T cell mediated cell death. 
To elucidate if BPTF KD cells are more antigenic than control cells, we used the 
OT1 and pmel CD8 T cell TCR transgenic models (392,393). The pmel TCR recognizes 
peptides from the endogenously expressed Pmel, whereas the OT1 TCR recognizes 
peptides from chicken Ovalbumin (OVA) presented by H2-Kb, which is expressed on 
B16F10, but not 4T1 (392,393). 
Coculture experiments show that neither pmel nor OT1 CD8 T cells had 
enhanced reactivity to BPTF KD B16F10 cells (Fig. 3.7C and D) even though they 
expressed equivalent OVA and increased PMEL protein (Fig. 3.7E and F). Consistent 
with BPTF-independent OVA antigen presentation, an antibody which recognizes the 
OVA peptide (SIINFEKL) in context with H2-Kb equivalently stains control and BPTF KD 
B16F10 cells (Fig. 3.7G) (394). To further characterize the CD8 T cell response to  
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known antigens, we quantified gp100, TRP2, and p15E reactive intratumoral CD8 T 
cells by ELISPOT. From this we observed similar numbers of peptide reactive CD8 T 
cells between control and BPTF KD tumors (Fig. 3.7H). Together, these results suggest 
that enhanced CD8 T cell activity to BPTF KD tumors occurs due to novel antigens.  
To ascertain if BPTF KD cells present novel antigens, we cloned CD8 T cells 
from both BPTF KD and control tumor bearing mice. Coculture assays showed 
enhanced activity of CD8 T cell clones from BPTF KD tumor bearing mice to BPTF KD 
target cells compared to similar experiments using controls (Fig. 3.7I). Furthermore, this 
enhanced activity usually occurs only when cocultured with BPTF KD, but not control, 
target cells (5 of 9 assayed clones)(Fig. 3.7J). In contrast, we do not observe enhanced 
cytolytic activity when CD8 T cells isolated from control tumor bearing mice are 
cocultured with BPTF KD target cells (0 of 4 assayed clones)(Fig. 3.7J). These results 
support the hypothesis that BPTF KD tumors express novel antigens. 
3.6 BPTF Directly Regulates Antigen Processing 
To identify BPTF-dependent genes which could alter tumor cell antigenicity, we 
performed genome wide expression arrays on 4T1 tumors harvested from NSG mice 
(Fig. 3.8A). We observed 115 upregulated genes and 199 downregulated genes (>1.5 
fold change in expression, FDR<0.05)(Fig. 3.8A). Of genes identified, we focused on 
Psmb9 because it regulates antigenicity as a subunit of the immunoproteasome (395). 
We confirmed Psmb9 upregulation in vitro, and observed elevated expression of the 
neighboring antigen processing genes Psmb8, Tap1 and Tap2 in both tumor models, 
though these genes were not significantly upregulated in our microarrays (Fig. 3.8B and 
C). The upregulation of these genes correlates with equivalent to slight increases in cell  
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surface expression of H2K or H2D in BPTF KD cells as measured by mean 
fluorescence intensity (MFI), which were not the result of increased gene expression 
(Fig. 3.8D-F). In addition, the expression of the interferon inducible genes Oas1a and 
Oas2 were not upregulated with BPTF KD, indicating that upregulation of Psmb8, 
Psmb9, Tap1 and Tap2 are not a result of a general interferon response (Fig. 3.8G). 
To determine if BPTF directly regulates the expression of Psmb8, Psmb9, Tap1 
and Tap2, we measured BPTF occupancy by chromatin immunoprecipitation (ChIP) 
(396). Sites chosen for ChIP were guided by previously identified DNaseI 
hypersensitivity hotspots, and therefore possible regulatory elements, from genome 
wide studies done in the 3134 mouse mammary epithelial cell line (Fig. 3.9A) (397). The 
most consistent enrichment of BPTF between 4T1 and B16F10 was detected at the 
promoters, consistent with BPTF directly repressing these genes (Fig. 3.9B and C). To 
determine if BPTF chromatin remodeling activity could be relevant to changes in gene 
expression, we focused on the well characterized Psmb9-Tap1 divergent promoter 
(398), using formaldehyde assisted isolation of regulatory elements (FAIRE) (399). With 
this technique, open chromatin is isolated from fixed cells using phenol extractions and 
quantified by qPCR relative to a BPTF independent reference site. FAIRE shows that 
BPTF maintains chromatin structure of the Psmb9-Tap1 promoter in both cell lines (Fig. 
3.9D). 
To verify that increased expression of the immunoproteasome subunits is 
responsible for the enhanced antigenicity of BPTF KD cells, we utilized the PSMB8 
selective inhibitor ONX-0914 (400). Cytotoxicity assays show that enhanced CD8 T cell 
cytotoxicity to BPTF KD targets is ablated after treatment with ONX-0914 (Fig. 3.9E).  
115 
 
  
116 
 
 
117 
 
   
118 
 
 
119 
 
These results allow us to propose a model where BPTF depletion upregulates the 
antigen processing genes Psmb8, Psmb9, Tap1 and Tap2, which results in enhanced 
antigenicity and improved T cell antitumor immunity. As a corollary, we propose that 
BPTF normally suppresses antitumor immunity by repressing antigen processing in 
cancer cells (Fig. 3.10).  
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Chapter 4 
BPTF Inhibits the NK Cell Antitumor Response by Suppressing Natural 
Cytotoxicity Receptor Co-ligands 
 
4.1 NK Cell-Mediated Antitumor Immunity is Enhanced to BPTF-Depleted Breast 
Tumors 
To further investigate roles for NURF in breast cancer cell biology, we transduced the 
well-established 67NR and 66cl4 mouse breast cancer cell lines with retroviruses 
expressing control or BPTF shRNAs (Fig. 4.1A) (376). In culture we observed 
equivalent doubling times, cellular morphology, and levels of apoptosis for BPTF KD 
cells compared to controls (Fig. 4.1B-D). Control and BPTF KD 66cl4 or 67NR lines 
were then transplanted into the 4th mammary fat pad of syngeneic BALB/c mice. After 
3-4 weeks, we observed reduced weight of BPTF KD tumors compared to the controls, 
consistent with results observed the 4T1 and B16F10 lines (Fig. 4.2A). Tumor weights 
were used instead of volume to measure growth because BPTF KD tumors grow flat, 
confounding volume-based comparisons to controls (see Fig. 3.2). Microarray 
expression profiling of control and BPTF KD tumors discovered an enrichment of genes 
with gene ontology (GO) terms which included immune response descriptors (Fig. 
4.2B). In agreement with microarray data, KEGG analysis of a combined gene list from 
both tumor types also identified an abundance of genes involved in the immune 
response, immune cell signaling, and chemokine signaling (Fig. 4.2C) (401). To confirm 
the importance of the immune response for BPTF KD tumor growth, our tumor growth 
studies were repeated in an immune deficient NSG background. These experiments  
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showed equivalent BPTF KD tumor weights to controls, demonstrating the immune 
system is required to reduce the growth of BPTF KD tumors (Fig. 4.2D). 
To identify immune cells that are important for reducing BPTF KD tumor weights, 
we repeated our tumor growth studies in mice depleted of NK cells, CD8+ T cells, or 
CD4+ T cells by mAb treatments. We observed improved growth of 67NR and 66cl4 
BPTF KD tumors with NK cell depletion, but not with CD8+ or CD4+ T-cell depletion, 
indicating that NK cells are required for reduced BPTF KD tumor growth (Fig. 4.2E). 
Surprisingly, control 66cl4 tumor weights were reduced with NK depletion, suggesting 
tumor promoting NK cell functions in this tumor type (see discussion)(Fig. 4.2E). 
4.2 NK Cell Cytotoxic Activity is Enhanced to BPTF Depleted Cancer Cells In Vitro 
Coculture of purified splenic mouse NK cells with 67NR and 66cl4 cells showed 
enhanced NK cell cytolytic activity against BPTF KD targets (Fig. 4.3A). To determine if 
BPTF KD cells are more sensitive to NK cell-mediated killing, the cytolytic activities of 
NK cells were activated independent of ligand using PMA + ionomycin (P+I). P+I 
activated NK cells killed control and BPTF KD targets equivalently in coculture, 
indicating that BPTF KD targets are not more sensitive to lysis by NK cells (Fig. 4.3B). 
To determine if soluble factors secreted by BPTF KD targets enhance NK cell activity, 
mouse NK cells were pre-incubated with media from cultured control or BPTF KD 67NR 
or 66cl4 tumor cells prior to their use in the cytolytic assay. From these experiments, we 
observed enhanced NK cell cytolytic activity toward BPTF KD targets independent of 
preconditioning with media from control or BPTF KD cultures (Fig. 4.3C). These results 
in combination demonstrate that changes on the surface of BPTF KD tumor cells 
improve NK cell activation and cytolytic activity. 
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4.3 BPTF Regulates Cell Surface HSPG Abundance and Hpse Expression 
We conducted microarray gene expression analyses of control and BPTF KD 67NR and 
66cl4 tumors from NSG mice to identify candidate BPTF-regulated NK cell receptor 
ligands on tumor cells. Tumors from NSG mice were used for these analyses because 
they lack gene expression changes resulting from tumor infiltrated immune cells, and 
therefore could more reliably identify BPTF-regulated gene targets. Analysis of these 
data sets focused on activating receptor ligands because the inhibitory MHC ligands are 
not significantly BPTF regulated in 67NR or 66cl4 cells (Fig. 4.4A). Our microarray 
experiments identified two BPTF regulated genes with functions in HS metabolism but 
did not identify any known activating NK cell receptor ligands (Fig. 4.4B and C). HS and 
HSPGs are well characterized co-ligands for the NCRs, which are required for efficient 
NK cell-mediated tumor cell killing (402). Unfortunately, the main HS metabolizing 
enzyme, heparanase, was not included on the microarray design. To compensate, we 
used qRT-PCR to measure its gene expression from the tumor samples and discovered 
significant reductions in Hpse transcripts with BPTF KD (Fig. 4.4B).  
Because HS is a known co-ligand to all NCRs, it seemed plausible that the 
enhanced NK cell cytolytic activity to BPTF KD cells occurs through the NCRs. 
Consistent with these results, a similar reduction in mouse NK cell cytolytic activity was 
observed to BPTF KD 66cl4 cells after NCR1 blocking (Fig. 4.4D) (403). Also, the 
addition of the NCR competitive inhibitor heparin erased the mouse NK cell cytolytic 
activity against 67NR and 66cl4 BPTF KD targets (Fig. 4.4E) (82). These results 
support the hypothesis that BPTF has functions in regulating the abundance of NCR 
ligands on tumor cells to influence NK cell cytolytic activity. 
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A recombinant NCR1-Ig fusion protein was then used to measure the abundance 
of NCR1 ligands on the surface of BPTF KD 67NR and 66cl4 cells. From these 
experiments, we discovered enhanced binding of NCR1-Ig to BPTF KD cells compared 
to controls (Fig. 4.4F and G). These results demonstrate that enhanced NK cell cytolytic 
activity results from an overabundance of NCR1 ligands.  
The major regulator of cell surface HS abundance, in the form of HSPGs, in 
mammals is heparanase (404). Our expression analysis identified Hpse as a BPTF-
regulated gene in both 67NR and 66cl4 BPTF KD tumors (Fig. 4.4B). These results 
were confirmed in culture for the 67NR and 66cl4 cells and in three human lines (Fig. 
4.5A and B). Consistent with reductions in Hpse gene expression, Western blotting 
discovered significant reductions of cell surface HPSE abundance with BPTF KD (Fig. 
4.5C). The importance of reduced cell surface HPSE for enhanced NK cell binding to 
BPTF KD cells was investigated using bacterial heparinase treatments. Pretreatment of 
66cl4 tumor cells with bacterial heparinase suppressed the enhanced binding of NCR1-
Ig to BPTF KD cells (Fig. 4.5D). Bacterial heparinase pretreatment also reduced the 
enhanced activity of NK cells to BPTF KD targets (Fig. 4.5E). These results suggest that 
increases in HS abundance on HSPGs with BPTF KD results in enhanced NK cell 
cytolytic activity. To determine if decreased Hpse expression with BPTF KD correlates 
with changes in cell surface HSPGs, we measured HSPG abundance by Western 
blotting cell surface protein extractions using antibodies to HS. Three HSPGs from 
these experiments had increased levels in BPTF KD cells: a ~150 kDa band, a ~55 kDa 
band and a ~45 kDa band (Fig.4.5F – see arrows). It is unlikely that expression of the  
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HSPG core proteins are BPTF-dependent because they were not BPTF-dependent 
from the microarray analyses (Fig. 4.5G). Additionally, only the MMP2 HSPG sheddase 
was deregulated in 67NR, but not 66cl4, BPTF KD NSG tumors suggesting that HSPG 
cell surface shedding is not BPTF-dependent (Fig. 4.5G). BPTF functions in regulating 
Hpse expression could be direct because ChIP revealed BPTF occupancy broadly 
localized at the Hpse gene in 67NR and localized at the Hpse promoter in 66cl4 (Fig. 
4.5H). These results suggest that BPTF regulates Hpse expression, possibly through 
direct functions at its promoter. From these results, we propose a model where NURF 
directly activates Hpse in cancer cells, elevating cell-surface heparanase and reducing 
cell-surface HSPGs. Because HSPGs are known co-ligands for NCRs, our model 
predicts that NURF suppresses direct NCR-mediated NK cytolytic activity by 
upregulating heparanase levels (Fig. 4.6). 
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Chapter 5 
Discussion and Future Directions 
5.1 Discussion 
Understanding how tumors escape the immune response is of great interest to 
tumor immunologists. Epigenetic escape mechanisms, most prominently DNA 
methylation and histone acetylation, suppress tumor cell antigenicity to inhibit T cells 
and ligand expression to inhibit NK cells (405). Because of its importance in gene 
expression, chromatin remodeling is predicted to have similar functions in tumor cells. A 
variety of approaches have been developed to improve antitumor immunity, including 
enhancing tumor cell antigenicity, blocking immunosuppressive checkpoints, enhancing 
effector cell functions and depleting immunosuppressive cell populations (406). Using 
several of these approaches in combination is likely required for lasting therapeutic 
outcomes due to tumor adaptation. For combinatorial treatment regimens to be 
effective, novel and varied means to enhance antitumor immunity must be developed. 
Toward this end, we investigated if the epigenetic regulator NURF regulates antitumor 
immunity and if it could be leveraged to develop a novel immunotherapeutic approach. 
5.1.1 NURF Depletion Enhances Tumor Cell Antigenicity and T Cell Antitumor 
Immunity 
 Consistent with NURF depletion improving antitumor immunity, we observed 
reduced tumor growth when either BPTF KD B16F10 cells are introduced into immune 
competent mice or when BPTF KD 4T1 cells are introduced into gemcitabine treated 
immune competent mice. In the case of 4T1, gemcitabine treatments are likely required 
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to remove the significant immunosuppressive effects MDSC cells have on CD8+ 
effector T cells in this model (407). We also show that 4T1 metastasis to the lung is 
correlated with tumor weight and not BPTF KD. Because tumor size is often correlated 
with metastatic burden, and BPTF KD tumors are smaller than control tumors, these 
results do not rule out a role for BPTF in metastasis. To better understand the effect of 
BPTF KD in metastasis, we would need to measure lung colony formation after tail vein 
injection of tumor cells to eliminate tumor burden as a factor. 
 ADCC studies showed that CD8+ and CD4+ T cells are required for enhanced 
antitumor immunity to BPTF KD 4T1 and B16F10 cells. CD8 and CD4 antigens are 
expressed prominently on CTLs and helper T cells, respectively, but are also expressed 
on other cell types including dendritic cells, B cells and macrophages (408,409). While 
these antigens are present on several cell types, the simplest interpretation of these 
results is that CD8+ and CD4+ T cells are essential for enhanced antitumor immunity to 
BPTF KD tumors. This conclusion seems plausible because CD8 T cells are major 
effectors of antitumor immunity to both mouse and human tumors and their activity 
requires CD4 T helper cell activity in vivo (410,411). While CD4 T cells predominantly 
have helper functions, they can directly promote antitumor immunity to MHC II 
expressing tumors (407). Direct CD4 T cell cytolytic activity to 4T1 and B16F10 tumors 
is unlikely but possible because we observe enhanced MHC II molecule expression on 
BPTF KD B16F10 cells.  
 Our flow cytometry analysis of tumors revealed that BPTF KD tumors have more 
intratumoral CD8 T cells and that the infiltrated CD8 T cells are more active in BPTF KD 
tumors compared to controls. Differences between the 4T1 and B16F10 tumor models 
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include CD44 and BTLA expression. Decreased CD44 expression on 4T1 tumors is 
likely the result of MDSC activity, which is known to suppress CD44, but not CD69, 
abundance on tumor infiltrated CD8 T cells (412). B16F10, however, does not induce 
MDSC amplification (413). Differences in BTLA could result because the 4T1 tumor 
microenvironment has elevated costimulatory signals compared with B16F10, 
preventing T-cell anergy (382). It is unlikely that BPTF regulates costimulatory 
molecules on the tumor because not all CD8 T cell clones are preferentially reactive to 
BPTF KD targets. 
 Because CD8 T cells are major effectors of antitumor immunity, we thought it 
plausible that the enhanced antitumor response observed in vivo is due to the direct 
antitumor functions of CD8 T cells. In vitro cytotoxicity assays support this model by 
showing that CD8 T cells primed and activated on BPTF KD tumors/cells have greater 
antitumor cytotoxic activity to BPTF KD target cells than compared to identical 
experiments using control tumors/cells. It is not likely that BPTF is a general regulator of 
antigen presentation because we observe approximately equivalent levels of cell 
surface H2K and H2D with BPTF KD. Because CD8 T cells, and not NK cells, respond 
to 4T1 and B16F10 BPTF KD tumors, it is plausible that BPTF KD improves antigen 
presentation rather than regulating immune cell checkpoints, which commonly regulate 
both NK and CD8 T cells (414,415). 
CD8 T cell activity requires that the TCR engages antigen:MHC complexes on 
the surface of target cells. The degree to which an antigen stimulates T cell activity 
depends on both the number of antigen:MHC complexes presented and the quality of 
the antigen (416,417). Peptides with greater antigenicity can either more favorably bind 
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to MHC or promote higher affinity TCR-antigen:MHC interactions (416). To determine 
whether BPTF suppresses the presentation of known antigens, we utilized OT1 and 
pmel transgenic CD8 T cells, and despite equal or enhanced expression of the 
ovalbumin and PMEL proteins, coculture experiments show that BPTF does not lend 
protection against OVA- and pmel-reactive CD8 T cells. These results indicate that 
BPTF represses the presentation of select antigens to CD8 T cells. If BPTF KD tumors 
present novel antigens to CD8 T cells, we would predict that CD8 T cell clones 
selectively reactive to BPTF KD targets would exist in mice bearing BPTF KD tumors. 
Toward testing this prediction, we cloned and assayed several CD8 T cell clones from 
mice bearing BPTF KD or control 4T1 tumors. Assay for cytolytic activity of CD8 T cell 
clones isolated from 4T1 BPTF KD tumor–bearing mice identified many clones with 
enhanced reactivity specifically toward BPTF KD targets. These results are consistent 
with an increased antigenicity of BPTF KD cells, which primes the expansion and 
activation of CD8 T cells in BPTF KD tumor bearing mice. The identity of these antigens 
is currently unknown but they likely result from BPTF regulating presentation of TSA or 
TAA (411). Either class of these tumor antigens could be upregulated with BPTF KD, 
improving tumor cell antigenicity. Our microarray analysis of 4T1 tumors did not reveal 
any known tumor antigens, but these results would not detect differences in expression 
of alloantigens. The 4T1 tumor line has a BALB/cfC3H hybrid genotype, and therefore 
presents alleles from the C3H background, which would be recognized as alloantigens 
in BALB/c mice (376). 
 In addition to the presentation of TAA and TSA, novel antigens can be created by 
changes in the antigen processing machinery. From our experiments, we observe that 
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BPTF represses the expression of Psmb8, Psmb9, Tap1, and Tap2 in both 4T1 and 
B16F10. Upregulation of the immunoproteasome subunits Psmb8 and Psmb9 with 
BPTF depletion would result in increased immunoproteasome activity, generating more 
antigenic peptides (48,395,418). Peptides with greater antigenicity can more favorably 
bind to MHC molecules or promote higher affinity interactions with the TCR (416). In 
addition, upregulation of the TAPs alters the repertoire of peptides presented by 
changing the types of peptides transported into the endoplasmic reticulum for loading 
into MHC molecules (50). NURF’s function in regulating the expression of these genes 
could be direct because BPTF is localized to their promoters by ChIP. BPTF also 
occupies distal elements, most significantly in 4T1, which could also influence gene 
expression. How NURF is recruited to these genes is not known. Once recruited, NURF 
could remodel chromatin structure to regulate gene expression. This model is supported 
by an observed change in chromatin structure by FAIRE at the Psmb9-Tap1 promoter 
with BPTF KD. FAIRE is a low resolution method of interrogating chromatin structure 
and it is difficult to translate these results into understanding how NURF remodels 
chromatin to regulate the expression of these genes. Psmb8, Psmb9, Tap1, and Tap2 
promoters are regulated by IFNγ through the STAT1 and IRF-1 transcription factors 
(419,420), and are repressed in tumor cells by DNA methylation and histone 
deacetylation (237,238,421). Our finding that BPTF represses their expression, 
presumably through the NURF complex, presents a novel epigenetic mechanism to 
suppress tumor cell antigenicity. 
As with most therapies, a potential NURF inhibitor would be more effective when 
used in combination with other chemo or immunotherapies. BPTF depletion improves 
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antigenicity, but these effects are only relevant for antitumor immunity when MDSC 
abundance is low, hence the need to use gemcitabine to deplete MDSCs in the 4T1 
model. In contrast, the B16F10 model has low levels of MDSC, not requiring the use of 
gemcitabine (413). The contrast between these two tumor models provides proof of 
principle for the utility of a NURF inhibitor in combinatorial therapeutic regimens. 
5.1.2 BPTF Inhibits the NK Cell Antitumor Response by Suppressing Natural 
Cytotoxicity Receptor Co-ligands 
Using the 67NR and 66cl4 transplantable tumor models, we discovered a second 
mechanism by which BPTF, and by extension the NURF chromatin remodeling 
complex, represses antitumor immunity. We show that, besides suppressing CD8 T cell 
antitumor activity, BPTF represses NK-mediated antitumor activity. Our mAb 
experiments show that NK cells are necessary for BPTF KD 67NR and 66cl4 reduced 
tumor growth. While most prominently expressed by NK cells, asialo-GM1 is also 
expressed by a small subset of monocytes and macrophages and by all basophils 
(422,423). The most likely interpretation of our depletion studies is that NK cells are 
essential for enhanced antitumor immunity to BPTF KD tumors because asialo-GM1 
treatment does not affect the antitumor activities of monocytes or macrophages, and 
basophils are not relevant to tumor immunoediting (422). Interestingly, we also 
observed pro-tumor NK cell activities to 66cl4 tumors from our in vivo mAb blocking 
experiments. NK cells are known to control the immune response by direct killing of 
DCs and T cells, which would suppress an adaptive immune response to 66cl4 tumors 
(424). Additionally, a subset of regulatory NK cells have recently been identified which 
suppress tumor infiltrating T cell cytokine production and proliferation (425). It is 
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certainly possible that the large number of infiltrating NK cells in the 66cl4 tumors could 
have these functions.  
 NK cell antitumor activity is regulated by a balance of activating and inhibitory 
receptors which recognize ligands on tumor cells (166). To identify BPTF-dependent NK 
receptor ligands we used microarrays to discover BPTF-regulated NK receptor ligands. 
Narrowing our search to activating receptors, we discovered that components of the HS 
synthesis and degradation pathways are BPTF-dependent in tumors. The most 
noteworthy BPTF-regulated factor discovered was the HS degrading enzyme 
heparanase. BPTF functions regulating Hpse are likely direct because it is localized to 
its regulatory elements when measured by ChIP. Changes in HS and HSPGs seemed 
plausible because they are highly conserved, common co-ligands to all NCRs, and they 
influence NK cell-mediated antitumor immunity in both humans and mice (78,82,118). 
Consistent with BPTF regulating NCR co-ligands, NCR1 antibody blocking and heparin 
competitive inhibition reduced the enhanced NK cell cytolytic activity to BPTF KD 
targets. Furthermore, Western blotting identified HS modified glycoproteins which 
increase in abundance on the surface of BPTF KD cells. Heparanase binds HSPGs, 
stimulating endocytosis and eventually HS cleavage (426). These activities, which 
would be inhibited by reduced heparanase, could explain increased cell surface HSPG 
levels on BPTF KD cells as observed by Western blotting. We think it unlikely that 
reductions in HSPGs are due to reduced core protein expression, or increased activity 
of sheddases, because they are not deregulated in our microarray analyses. These 
results in total suggest a model where BPTF upregulates heparanase expression to 
down regulate cell surface HS levels, reducing NK cell cytolytic activity. 
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The significance of BPTF, and by extension the NURF complex, regulation of 
Hpse in cancer cells could have broader implications beyond regulating NK cell activity. 
Hpse is commonly upregulated in cancer cells to remodel the extracellular matrix to 
impact angiogenesis, metastasis, tumor growth and inflammation (118). It is therefore 
plausible that differences in tumor shape with BPTF KD could result from abnormal 
angiogenesis or establishing a fibrin shell (118). Also, decreases in heparanase levels 
could contribute to defects in metastases, as previously observed with BPTF KD 
melanoma tumors (375).  
 NK cells have greatest therapeutic significance to hematological malignancies, 
where NK cell activity can result in disease remission. NK cell activity against solid 
tumors is less significant because the immune suppressive TME inhibits NK cell 
infiltration and activity (427). Developing methods to circumvent the suppressive TME 
are required if NK cell therapies are to be pursued. We show for the first time that 
depleting BPTF in the TME could circumvent problems inherent to the use of NK cells 
as an immunotherapy toward solid tumors.  
5.1.3 NURF as a Therapeutic Target 
The observation that NURF depletion can improve the immunogenicity of tumor 
cells suggests that it could be pursued as a therapeutic target to improve tumor 
antigenicity or NK receptor co-ligand expression. Pursuing NURF as a novel therapeutic 
target for small molecule design is plausible. First, the NURF subunits Bptf, Snf2l and 
Rbap46/48 are rarely deleted and frequently amplified or overexpressed in cancer cells, 
suggesting that a majority of tumor cells will have a NURF complex to inhibit (346,366). 
Second, BPTF is not necessary for the viability of any primary cell type examined, 
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suggesting that NURF inhibition may be tolerated in adults (350,351,355). Third, NURF 
is an enzyme with several substrate binding sites including DNA, histones and ATP, 
each of which could be targeted by small molecule inhibitors. In addition to substrate 
binding sites, NURF is recruited to chromatin through interactions with transcription 
factors, DNA and modified histones, each of which could also be inhibited by small 
molecules (345). Proof of principle for this approach is shown by the BET family of 
chromatin associated proteins which have important functions in regulating oncogenes 
relevant to myelomas. Small molecules have been developed which bind to the 
bromodomain of the BET proteins, preventing it from interacting with chromatin, with the 
effect of reducing oncogene expression (428). BPTF has a similar bromodomain which 
could be targeted on the NURF complex. 
Other epigenetic modifiers like DNMTi and HDACi are used clinically for cancer 
treatment. These therapies, however, are not effective at treating solid tumors and must 
be used in combination with other chemo or immuno therapies to see significant 
therapeutic benefit (429-432). We found that BPTF depletion alone is enough to reduce 
both breast cancer and melanoma tumor growth in mice, suggesting that targeting 
BPTF could be a more effective antitumor treatment than current epigenetic targets. 
As with targeting any epigenetic modifier, we would expect there to be off-target 
effects of NURF inhibition. While there have not been any inhibitors targeting chromatin 
remodeling complexes to enter clinical trials, examples can be drawn from DNMTi and 
HDACi. DNMTi were initially used at high doses, which resulted in severe toxicities. 
However, lowering the dose of DNMTi treatments eliminated the off-target toxicities, 
while still remaining therapeutically beneficial for hematological malignancies (433). It is 
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therefore possible that low dose treatment with a future NURF inhibitor could also be 
effective with limited off-target toxicity. HDACi, on the other hand, can cause significant 
cardiotoxicity, among other effects like thrombocytopenia and anemia (434). These off-
target toxicities result from the fact that the inhibitors are not specific to individual HDAC 
isoforms. For example, FDA approved vorinostat is a pan-HDACi that is active against 
all isoforms and romidepsin is active against HDAC1, 2 and 3. Developing inhibitors 
specific to a single HDAC isoform is a major area of research with the idea of 
minimizing these significant cytotoxicities (435). BPTF, on the other hand, only exists as 
one isoform, so isoform related off-target effects would not be an issue moving forward. 
Therefore, based on toxicities associated with targeting other epigenetic modifiers, it 
seems likely that a BPTF inhibitor at the right dose could have minimal off-target 
toxicity.  
It is very likely that a potential NURF inhibitor could synergize with currently used 
immune modulators which target other epigenetic regulators. For example, DNMTi are 
anticancer drugs which work in part by re-expressing silent tumor antigens and 
stimulating a CD8 T cell response, but these inhibitors also induce Hpse expression, 
possibly promoting cancer biology (102,120). It is conceivable that a NURF inhibitor, in 
combination with DNMTi, could limit heparanase upregulation and also synergize with 
the beneficial CD8 T cell antitumor immune response by enhancing NK cell antitumor 
activities.  
5.2 Future Directions 
We discovered that both CD4 and CD8 T cells are essential for enhanced 
antitumor immunity to BPTF KD 4T1 and B16F10 tumors. To determine if CD8 T cells 
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are sufficient for this enhanced antitumor immunity, ACT experiments reconstituting the 
immune system of T cell deficient RAG mice with tumor primed and activated CD8 T 
cells would be necessary. Our cytotoxicity experiments show that BPTF KD 4T1 and 
B16F10 tumor cells present novel antigens to CD8 T cells. Tumor cell vaccination 
studies would discover if BPTF KD cells provide better protection than control cells to 
challenge with BPTF KD tumor cells. If so, this would confirm that novel antigens are 
relevant in vivo to reduced BPTF KD tumor growth. To determine the identity of these 
antigenic peptides, we could remove peptides from MHC receptors by mild acid elution 
and identify and relatively quantify antigens by liquid chromatography-mass 
spectrometry (LC-MS) and MS/MS. Antigens eluted from control cells can then be 
compared to those eluted from BPTF KD cells to identify which antigens are exclusively 
expressed by BPTF KD cells (436,437). Alternatively, CD8 T cell clones isolated from 
BPTF KD tumor bearing mice could be used in shRNA KD screens to identify the genes 
which encode the reactive peptides (438). To achieve this, we could clone the TCR of a 
CD8 T cell clone that exhibits enhanced reactivity to BPTF KD targets and stably 
transfect it into 4G4 TCR negative mouse thymoma cells. These 4G4 cells can then be 
used to measure cytotoxicity toward BPTF KD targets transfected with pools of shRNA. 
Using this strategy, we could narrow down and identify the gene responsible for 
generating the antigen recognized by the TCR. In addition, our depletion studies 
revealed that BPTF KD 67NR and 66cl4 tumor growth is dependent on NK cell-
mediated antitumor immunity. As asialo-GM1 is not specific to NK cells, ACT 
experiments reconstituting the immune system of immunodeficient NSG mice with NK 
cells would verify if NK cells are sufficient for mediating the reduction of BPTF KD tumor 
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growth. Our cytotoxicity experiments revealed that mouse NK cells have enhanced 
activities toward BPTF KD tumor cells in vitro. Further work by our lab discovered that 
human NK-92 cells also exhibit enhanced reactivity toward both mouse and human 
BPTF KD tumor cells, indicating that this mechanism is conserved between mouse and 
human (data not shown). To determine if primary human NK cells also have increased 
activities to BPTF KD cells, we could isolate human NK cells from donors and perform 
in vitro cytotoxicity assays with both mouse and human targets. Our work discovered 
that the NCR1 receptor is necessary for enhanced NK cell cytotoxicity toward BPTF KD 
targets in vitro. To determine if NCR1 is relevant for enhanced NK cell-mediated 
antitumor immunity in vivo, we have treated tumor bearing mice with an NCR1 blocking 
antibody and observed rescue of BPTF KD 67NR and 66cl4 tumor weights (data not 
shown). 
We discovered that BPTF binds to the promoters of Psmb8, Psmb9, Tap1, Tap2 
and Hpse, suggesting direct regulation of their expression. Future experiments to 
determine how NURF regulates these promoters could include measurements of 
nucleosome occupancy to translate NURF nucleosome remodeling activity to 
transcription factor binding site accessibility and elevated gene expression. 
Transcription factors recruit NURF to genes, where it then remodels the chromatin to 
affect gene expression. Though many NURF interacting transcription factors have been 
identified, we do not know what transcription factors recruit NURF to the Psmb8, 
Psmb9, Tap1, Tap2 and Hpse promoters. We could identify these transcription factors 
by making a deletion series of these promoters and testing activity with a luciferase 
reporter assay. Analysis of the minimal DNA sequence which specifically stimulates 
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luciferase expression in BPTF KD 4T1 and B16F10 cells (for Psmb8, Psmb9, Tap1, 
Tap2) or specifically inhibits luciferase expression in BPTF KD 67NR and 66cl4 cells 
(for Hpse) could reveal known NURF recruiting transcription factor binding sites. 
We have identified two different mechanisms for BPTF in suppressing antitumor 
immunity. There are several possible explanations why 4T1 and B16F10 BPTF KD 
tumors are more sensitive to a CD8 T cell mediated response while 67NR and 66cl4 
BPTF KD tumors are more sensitive to a NK cell mediated response. First, it is possible 
that Psmb8, Psmb9, Tap1 and Tap2 expression are not BPTF-dependent in 67NR and 
66cl4 cells and that Hpse expression is not BPTF-dependent in 4T1 and B16F10. This 
is feasible because NURF is a cell type specific regulator of gene expression (351). If 
this is the case, our work could still translate to humans. For example, we show that in 
three human cell lines, MDA-MB-436, T47D and SH-SY5Y, heparanase expression is 
decreased with BPTF KD. We further observe enhanced cytolytic activity of NK-92 cells 
toward these BPTF KD human targets, which is NKp30 dependent (data not shown). 
Therefore, while individual human tumors could respond differently to BPTF KD, we 
have some evidence showing conservation of the NK cell-dependent model between 
mice and humans. qPCR and Western blotting would discover if expression of PSMB8, 
PSMB9, TAP1 and TAP2 are BPTF-dependent in human tumor lines. Second, these 
five genes could be BPTF-dependent in all four cell lines, but the high level of NK cell 
infiltration into the 67NR and 66cl4 TME could make NK cells more relevant to BPTF 
KD 67NR and 66cl4 antitumor immunity, while the lack of NK cell infiltration into 4T1 
and B16F10 tumors makes CD8 T cells most relevant to BPTF KD 4T1 and B16F10 
antitumor immunity. Third, another, or multiple, undiscovered mechanisms could affect 
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how sensitive these lines are to CD8 T or NK cells. For example, 4T1 and B16F10 cells 
could express high levels of ligand(s) to NK inhibitory receptors, such as Qa1. 
Alternatively, 67NR and 66cl4 cells could secrete high levels of T cell 
immunosuppressive cytokines, or cytokines which promote Treg differentiation. Flow 
cytometry to assess CD4 T cell subsets in the TME would address whether or not BPTF 
KD affects, either directly or indirectly, CD4 T cell differentiation. qRT-PCR and Western 
blotting would determine in which cell lines these genes are BPTF-dependent, and in 
vitro cytotoxicity assays would determine if BPTF KD 67NR and 66cl4 are more 
sensitive to CD8 T cells than controls, and if BPTF KD 4T1 and B16F10 cells are more 
sensitive to NK cells than controls.  
As with any cancer therapy, combination therapy with BPTF depletion could 
enhance the antitumor effects seen beyond those observed for individual therapies. A 
NURF inhibitor could possibly synergize with checkpoint blockade therapy, which 
enhances T and NK cell activation levels. These activated effector cells are only 
effective if tumors express tumor antigens and NK receptor ligands, both of which are 
commonly suppressed by tumor cells. Enhanced tumor cell antigenicity or cell surface 
HS following BPTF inhibition could make the tumor a better target for the un-
suppressed CD8 T and NK cells during checkpoint blockade. Further, this reasoning 
could also apply to synergy of BPTF inhibition with T cell or NK adoptive cell therapy. To 
test these theories, tumor studies combining PD-1 and/or CTLA-4 mAb treatment with 
BPTF depletion could be performed (439). Additionally, donor mouse T cells or NK-92 
cells could be adoptively transferred into control or BPTF KD tumor bearing 
immunodeficient NSG mice (440). Changes in tumor growth could be compared to 
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those seen alone with BPTF KD, checkpoint blockade, or ACT treatment. Because 
gemcitabine promotes BPTF-dependent reductions in 4T1 tumor growth, it is 
reasonable to suggest that BPTF depletion could also synergize with other 
chemotherapies which stimulate antitumor immune responses. For example, our breast 
tumor studies can be repeated in combination with doxorubicin or paclitaxel treatment, 
two chemotherapeutic agents with immune-modulatory effects used to treat breast 
cancer (215).  
 NK cells have essential functions in targeting metastasizing tumor cells via NCR1 
(78,441). The observation that BPTF promotes cell surface heparanase expression 
warrants more detailed studies on roles for BPTF during metastasis. This could be 
addressed using models of spontaneous metastasis or lung colonization of tumor cells 
after tail vein injection (442). If defects in metastasis are observed, the role of NK cells 
can be studied using either NK mAb depletion or NK deficient NCR1 KO mice. 
This study identifies NURF as a potential novel therapeutic target to improve 
tumor cell immunogenicity. To further this work, we will need to determine if there is a 
correlation between low NURF expression and a better response to immunotherapy for 
human tumors. Experiments solidifying the role of NURF in repressing CD8 T cell and 
NK cell mediated antitumor immunity and in determining off-target effects of NURF 
depletion in vivo would also need to be done. Our tumor studies examine the role of 
BPTF when depleted prior to tumor inoculation into mice, and thus prior to the induction 
of the antitumor immune response and the establishment of an immunosuppressive 
tumor microenvironment. Because tumors that present in the clinic are in the escape 
phase, it will be necessary to determine if BPTF depletion in established tumors can 
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enhance the suppressed antitumor immune response. We have preliminarily tested this 
by injecting established 4T1 and 66cl4 tumors with recombinant adenovirus (rAd) 
expressing control or BPTF shRNA and we observed reduced BPTF KD tumor growth 
and enhanced CD8 T or NK cell activation in BPTF KD tumors (data not shown). The 
antitumor immune response to BPTF depletion could also be examined in spontaneous 
tumors by injecting control or BPTF rAd into MMTV-PyMT tumors and monitor for 
changes in tumor growth and antitumor immunity. Another step toward determining if 
BPTF can be targeted therapeutically is to assess the potential off-target effects of 
BPTF depletion in vivo. Importantly, BPTF KO in adult mice did not result in any 
apparent toxicities, mice were viable, and necropsy at sacrifice did not reveal any 
abnormal pathologies (data not shown). These preliminary experiments suggest that a 
systemic BPTF inhibitor would not be toxic to adult tissues. However, a systemic drug to 
BPTF would inhibit BPTF in tumor infiltrated immune cells as well as in tumor cells and 
could affect their activities. Importantly, inhibitors of other epigenetic modulators have 
some negative effects on immune cell function. For example, DNMT and HDAC 
inhibitors suppress NK activating receptor expression, including NKp46, and promote 
NK cell apoptosis (443,444). We have determined that BPTF KD in T cells and NK cells 
does not affect their cytotoxic activities in vitro (data not shown), but in vivo studies 
would be necessary for assessing the effect of BPTF depletion on non cytotoxic 
immune cells that are necessary for establishing the antitumor immune response. In 
vivo studies inoculating a Dox inducible conditional BPTF KO mouse with Dox inducible 
conditional BPTF KO tumor cells and measuring tumor growth and NK/CD8 T cell 
activation would address this question. Because BPTF suppresses immunogenicity, 
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another potential side effect associated with systemic BPTF inhibition could include 
autoimmunity. This issue would be difficult to address preclinically as mice are not good 
predictors of immune-related adverse events seen in humans following immunotherapy 
(445). However, the lack of toxicity seen in adult BPTF KO mice suggests that BPTF 
depletion may not result in severe autoimmunity. Finally, a good inhibitor to NURF must 
be developed before NURF can be targeted in the clinic. Currently there is only one 
BPTF inhibitor, AU1. AU1 is a bromodomain inhibitor with moderate potency to the 
BPTF bromodomain, making it not efficacious enough to use in vivo. Though the 
specificity of AU1 has not yet been tested, it is reasonable to expect that it may not be 
specific to BPTF as several other proteins contain similar bromodomains. Therefore, a 
more potent, and ideally specific, BPTF inhibitor must be developed. This could be 
achieved by screening small molecule compound libraries for compounds with BPTF 
inhibiting activity. 
Overall, this study reveals the chromatin remodeling complex NURF as a 
potential therapeutic target to enhance CD8 T and/or NK cell antitumor immunity. While 
chromatin remodeling complexes are implicated in contributing to diverse cancer types, 
we propose for the first time that a chromatin remodeling complex has functions in 
regulating tumor immunoediting. 
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